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Summary 
There is pressing urgency to understand the pathogenesis of the severe acute respiratory 
syndrome coronavirus clade 2 (SARS-CoV-2) which causes the disease COVID-19. SARS-
CoV-2 spike (S)-protein binds ACE2, and in concert with host proteases, principally TMPRSS2, 
promotes cellular entry. The cell subsets targeted by SARS-CoV-2 in host tissues, and the 
factors that regulate ACE2 expression, remain unknown. Here, we leverage human, non-human 
primate, and mouse single-cell RNA-sequencing (scRNA-seq) datasets across health and 
disease to uncover putative targets of SARS-CoV-2 amongst tissue-resident cell subsets. We 
identify ACE2 and TMPRSS2 co-expressing cells within lung type II pneumocytes, ileal 
absorptive enterocytes, and nasal goblet secretory cells. Strikingly, we discover that ACE2 is a 
human interferon-stimulated gene (ISG) in vitro using airway epithelial cells, and extend our 
findings to in vivo viral infections. Our data suggest that SARS-CoV-2 could exploit species-
specific interferon-driven upregulation of ACE2, a tissue-protective mediator during lung injury, 
to enhance infection.  
 
 
Introduction 
Human coronaviruses (CoVs) are single-stranded positive-sense RNA viruses that can cause 
mild to severe respiratory disease (Fung and Liu, 2019). Over the past two decades, zoonotic 
transmission events have led to the emergence of two highly pathogenic CoVs: severe acute 
respiratory syndrome (SARS)-CoV and Middle East respiratory syndrome (MERS)-CoV. SARS-
CoV-2, which causes the disease known as COVID-19, was first reported in late 2019 
(Coronaviridae Study Group of the International Committee on Taxonomy of, 2020; Lu et al., 
2020; Paules et al., 2020). COVID-19 is characterized by pneumonia, fever, cough and 
occasional diarrhea (Guan et al., 2020; Holshue et al., 2020; Huang et al., 2020), and SARS-
CoV-2 RNA has been reliably detected in nasopharyngeal swabs, sputum, and stool samples 
(Wang et al., 2020; Wolfel et al., 2020; Zou et al., 2020). As of April 19, 2020, SARS-CoV-2 
continues to spread worldwide, with over 2,401,379 total confirmed cases, 165,044 deaths, and 
623,903 recovered individuals in 185 countries/regions (Dong et al., 2020a). Early models of 
COVID-19 transmission dynamics estimate one infectious individual infects slightly over two 
individuals, with travel restrictions reducing spread to one individual, though these figures may 
evolve as more accurate epidemiological data become available (Kucharski et al., 2020). 
 
Work during the first SARS-CoV epidemic identified the human host factor angiotensin-
converting enzyme 2 (ACE2) as the receptor for SARS-CoV (Li et al., 2003). SARS-CoV-2 spike 
(S) protein has been experimentally shown to bind ACE2 on host cells with significantly higher 
affinity than SARS-CoV-S (Hoffmann et al., 2020; Wrapp et al., 2020). The main host protease 
that mediates S protein activation on primary target cells and initial viral entry is the Type II 
transmembrane serine protease TMPRSS2 (Glowacka et al., 2011; Hoffmann et al., 2020; 
Iwata-Yoshikawa et al., 2019; Matsuyama et al., 2010; Shulla et al., 2011; Walls et al., 2020). 
Other host proteases, such as furin, have also been suggested to promote the pathogenesis of 
this pandemic SARS-CoV-2 clade, but when and where they process S-protein remains to be 
determined (Bottcher-Friebertshauser et al., 2013; Bugge et al., 2009; Coutard et al., 2020; 
Walls et al., 2020). Binding of SARS-CoV-S to ACE2 results in receptor-mediated internalization 
(Grove and Marsh, 2011; Kuba et al., 2005). Importantly, ACE2 functions as a key tissue-
protective component during severe acute lung injury (Imai et al., 2005; Kuba et al., 2005). 
 
A tissue-level basis for understanding SARS-CoV tropism was proposed based on ACE2 
histological staining and expression in human epithelia of the lung and small intestine (Hamming 
et al., 2004; Harmer et al., 2002; Jonsdottir and Dijkman, 2016). However, unlike the specific 
expression of CDHR3 (the rhinovirus-C receptor), which is resolved to ciliated epithelial cells of 
the upper airway (Griggs et al., 2017), the specific cell subsets within each tissue that express 
ACE2 remain unknown. Identifying the cell subsets targeted by SARS-CoV-2 (ACE2+), and 
those at greatest risk of direct infection (ACE2+/TMPRSS2+), is critical for understanding and 
modulating host defense mechanisms and viral pathogenesis.  
 
After cellular detection of viral entry into a host cell, interferon (IFN) induction of interferon-
stimulated genes (ISGs) is essential for host antiviral defense in mice, non-human primates 
(NHPs) and humans (Bailey et al., 2014; Deeks et al., 2017; Dupuis et al., 2003; Everitt et al., 
2012; Schneider et al., 2014; Utay and Douek, 2016). There are three distinct types of IFNs: 
Type I IFNs (IFNα, IFNβ), Type II IFNs (IFNγ) and Type III IFNs (IFNλ) (Broggi et al., 2020; 
Muller et al., 1994; Stetson and Medzhitov, 2006). Each appears to converge on almost 
indistinguishable responses, mediated through the binding of STAT1 homodimers or STAT1/2 
heterodimers to ISGs. However, mounting evidence suggests that each type of IFN may have a 
non-redundant role in host defense or immunopathology, particularly at epithelial barriers 
(Broggi et al., 2020; Iwasaki et al., 2017; Iwasaki and Pillai, 2014; Jewell et al., 2010).  
 
 
While the host response to SARS-CoV highlighted a role for IFNs, most studies assessed the 
effect of IFN-restriction in cell lines that may not fully recapitulate the repertoire of ISGs present 
in primary human target cells (Bailey et al., 2014; de Lang et al., 2006; Sainz et al., 2004; Zheng 
et al., 2004). One study of SARS-CoV suggested the timing of the Type I IFN response is a key 
component of the in vivo response (Channappanavar et al., 2016). Clinical therapy using 
approved IFNs has been attempted for SARS-CoV, MERS-CoV and SARS-CoV-2 in the 
absence of a controlled trial to mixed effect, resulting in anecdotal evidence suggesting either 
rapid improvement or worsening of symptoms (Dong et al., 2020b; Lei et al., 2020; Li and De 
Clercq, 2020). Elucidating tissue and cell type specific ISGs and their activity is essential for 
understanding the role of IFNs in host defense during human SARS-CoV-2 infection.  
 
Massively-parallel single-cell RNA-sequencing (scRNA-seq) is transforming our ability to 
comprehensively map the cell types, subsets and states present during health and disease in 
barrier tissues (Ordovas-Montanes et al., 2020; Ordovas-Montanes et al., 2018; Smillie et al., 
2019). This has been particularly evident in the elucidation of novel human epithelial and 
stromal cell subsets and states (Ordovas-Montanes et al., 2018; Regev et al., 2017; Ruiz Garcia 
et al., 2019; Schiller et al., 2019; Smillie et al., 2019; Vieira Braga et al., 2019). Recently, 
scRNA-seq has been applied to better understand the cellular variation present during viral 
infection in vitro and in vivo (Russell et al., 2018; Steuerman et al., 2018). Global single-cell 
profiling efforts such as the Human Cell Atlas (HCA) initiative are ideally poised to rapidly share 
critical data and enhance our understanding of disease during emergent public health 
challenges (Sungnak et al., 2020).  
 
Here, using published and unpublished data sets (all from non-SARS-CoV-2 infected samples), 
we analyzed human, NHP, and mouse tissues that have been clinically identified to harbor virus 
in patients exhibiting COVID-19 symptoms. We provide a cautionary note on the interpretation 
of the scRNA-seq data presented below, as many factors such as dissociation, profiling method, 
and sequencing depth can influence results (STAR Methods). Here, we focus our analysis and 
discussion on the specific subsets where ACE2 and TMPRSS2 are enriched and relative 
comparisons within each dataset, rather than between datasets or equivalence to absolute 
numbers of total cells. Across several studies of human and NHP tissues, we find ISGs 
upregulated in ACE2 expressing cells.  
 
Strikingly, by treating primary human upper airway basal cells with distinct types of inflammatory 
cytokines, we find that IFNα drives ACE2 expression. Human influenza infection also induces 
broader expression of ACE2 in upper airway epithelial cells, and is corroborated by publicly 
available databases. Overall, our data provide motivation to better understand the trade-offs of 
combination antiviral/IFN therapy in humans infected with SARS-CoV-2 in order to balance host 
restriction, tissue tolerance, and viral enhancement mechanisms (Davidson et al., 2015; Fung 
and Liu, 2019; Imai et al., 2005; Iwasaki et al., 2017; Kuba et al., 2005; Lei et al., 2020; 
Medzhitov et al., 2012; Zou et al., 2014). Importantly, while our findings identify similar cell 
subsets enriched for Ace2 in mice, neither in vitro nor in vivo IFN-stimulation, nor in vivo viral 
challenge, substantially alter Ace2 levels. The dynamic, species-specific and multifaceted role of 
IFN raises implications for pre-clinical COVID-19 disease modeling.  
 
 
 
 
 
Results 
Lung Epithelial Cell Expression of Host Factors Used by SARS-CoV-2 in Non-Human 
Primates and Humans 
To investigate which cells within human and NHP tissues represent likely SARS-CoV-2 targets, 
we analyzed new and existing scRNA-seq datasets to assess which cell types express ACE2, 
alone or with TMPRSS2. In previously-unpublished NHP (Macaca mulatta) lung tissue collected 
following necropsy of healthy adult animals and analyzed using Seq-Well v1 (Gierahn et al., 
2017), we recovered at least 17 distinct major cell types, including various lymphoid, myeloid, 
and stromal populations (Figure 1A-C, Table S1, STAR Methods). ACE2 and TMPRSS2 were 
primarily expressed in epithelial cells, with 6.7% of type II pneumocytes expressing ACE2, and 
3.8% co-expressing ACE2 and TMPRSS2 (Figure 1B-C). Notably, the only double positive cells 
observed were classified within the type II pneumocyte population; however, we also identified 
TMPRSS2 expression within club cells, ciliated epithelial cells, and type I pneumocytes, albeit at 
diminished abundance and frequency compared to type II pneumocytes (Figure 1C, Table S1).  
 
Next, we compared ACE2+ with ACE2- type II pneumocytes to explore broader gene programs 
that differentiate putative SARS-CoV-2-target cells from cells of a similar phenotype and 
ontogeny (Figure 1D, Table S1). Among genes significantly upregulated in ACE2+ type II 
pneumocytes, we observed IFNGR2 (FDR-adjusted p = 0.022), a receptor for Type II IFN. 
Notably, previous work has demonstrated limited anti-viral potency of IFNγ for SARS-associated 
coronaviruses, compared to Type I IFN, at least in vitro (Sainz et al., 2004; Zheng et al., 2004). 
Other co-regulated genes of potential interest include TRIM27 (FDR-adjusted p = 0.025), as 
well as NT5DC1 (FDR-adjusted p = 0.003) and ARL6IP1 (FDR-adjusted p = 0.047), which were 
upregulated in the A549 adenocarcinoma alveolar basal epithelial cell line following exposure to 
IFNα and IFNγ for 6 hours (Sanda et al., 2006). We found IFNAR1 consistently expressed 
among both ACE2+ type II pneumocytes and ACE2+/TMPRSS2+ co-expressing type II 
pneumocytes, but its level of upregulation compared to all remaining pneumocytes did not meet 
statistical significance (FDR-adjusted p = 0.11). This analysis finds ACE2+ cells enriched within 
a rare fraction of secretory cells in NHPs, and that ACE2 expression is co-regulated with genes 
involved in IFN responses. 
 
To assess whether the findings from NHP lung cells were similarly present in humans, we 
analyzed a previously-unpublished scRNA-seq dataset derived from surgical resections of 
fibrotic lung tissue collected with Seq-Well S^3 (Hughes et al., 2019). Unsupervised analysis 
identified multiple cell types and subtypes of immune cells (Figure 2A-C, STAR Methods), as 
defined by genes displayed in Figure 2C (full lists available in Table S2). Here, we found that 
ACE2 and TMPRSS2 were primarily expressed within type II pneumocytes and ciliated cells, in 
line with our analysis of the NHP-derived cells (Figures 1, 2B). In type II pneumocytes 
(identified by unique expression of surfactant proteins SFTPC, SFTPB, SFTPA1), we found 
1.4% of cells expressing ACE2 (FDR-adjusted p = 1.35E-21), 34.2% expressing TMPRSS2 
(FDR-adjusted p < 1E-300), and 0.8% co-expressing both. In ciliated cells, we found 7% were 
ACE2+ (FDR-adjusted p = 5E-64), 24.6% were TMPRSS2+ (adjusted p = 3.8E-30), and 5.3% 
co-expressed both.  
 
As above, to assess for cellular pathways significantly co-expressed within putative target cells 
for SARS-CoV-2, we computed differentially expressed genes between ACE2+/TMPRSS2+ 
type II pneumocytes and all other type II pneumocytes (Figure 2C-D, Table S2). We found 
significant enrichment of BATF among ACE2+/TMPRSS2+ cells (FDR-adjusted p = 3.25E-7), 
which has been demonstrated previously to be upregulated by Type I and Type II IFNs (Murphy 
 
et al., 2013). Of note, we also observed TRIM28 co-expressed with ACE2 and TMPRSS2 
among type II pneumocytes in this dataset (adjusted p = 2.34E-9), which may play a role in 
potentiating an IFN response in lung epithelial cells (Krischuns et al., 2018). Within this cohort of 
donors, 3 individuals were human immunodeficiency virus (HIV)+ and diagnosed with active 
tuberculosis, 3 donors had active tuberculosis and were HIV-, and 2 were negative for both 
pathogens. Surprisingly, we found that all of the ACE2+ cells across all cell types were derived 
from HIV+ Mycobacterium tuberculosis (Mtb)+ donors despite approximately equivalent 
recovery of epithelial cell types from all donors (likelihood ratio test, p = 0.009, Figure 2E). 
Given limited cell and patient numbers combined with potential sampling biases, we caution that 
this observation requires much broader cohorts to validate a potential role for coinfections; still, 
we note our observation is suggestive of a role for chronic IFN in the induction of ACE2, as HIV 
infection is associated with persistent upregulation of ISGs and we observe elevated levels of 
IFNAR2, IFI30, and IKBKB (Utay and Douek, 2016) (FDR-adjusted p = 1.1E-6, 8.8E-9, 1.57E-7 
respectively; HIV+ vs. HIV- epithelial cells). 
 
Next, using a previously unpublished scRNA-seq dataset consisting of granuloma and adjacent, 
uninvolved lung samples from Mtb-infected NHPs collected with Seq-Well S^3 (Macaca 
fascicularis), we identified subsets of epithelial cells expressing ACE2 and TMPRSS2 (Figure 
S1, Table S3, STAR Methods). The majority of ACE2+/TMPRSS2+ cells were, once again, 
type II pneumocytes (22%) and type I pneumocytes (9.7%), and were largely enriched within 
granulomatous regions compared to adjacent uninvolved lung (Figure S1B-C, p = 0.006, Fisher 
Exact Test). ACE2+/TMPRSS2+ type II pneumocytes expressed significantly higher levels of 
antimicrobial effectors such as LCN2 (Figure S1D). Cells with club cell/secretory, type I 
pneumocyte, or ciliated phenotypes also contained some ACE2+/TMPRSS2+ cells, but we did 
not have sufficient power to detect significantly differentially expressed genes between these 
cells and other cells within those clusters. Taken together, we identify ACE2+/TMPRSS2+ cells 
in lower airways of humans and NHPs with consistent cellular phenotypes, and evidence 
supporting a potential role for IFN-associated inflammation in upregulation of these receptors.  
 
Small Intestinal Ileal Absorptive Enterocytes Express Host Factors Used by SARS-CoV-2 
Next, we examined several other tissues for ACE2 expressing cells based on the location of 
hallmark symptoms of COVID-19, with a focus towards the gastrointestinal tract due to reports 
of clinical symptoms and viral shedding (Xiao et al., 2020). Leveraging a previously unpublished 
scRNA-seq atlas of NHP tissues collected with Seq-Well v1, we observed that the majority of 
ACE2+ cells reside in the small intestine: principally within the ileum, jejunum, and, to a lesser 
extent, the liver and colon (Figure 3A, STAR Methods). Critically, we note that, in this 
experiment, the dissociation method used on each tissue was optimized to preserve immune 
cell recovery, and therefore under-sampled stromal and epithelial populations, as well as 
neurons from CNS tissue. Within the ileum, we identified ACE2+ cells as absorptive 
enterocytes, based on specific expression of ACE2 within cells defined by APOA1, SI, FABP6, 
and ENPEP, among others, by a likelihood-ratio test (Figure 3B-C, p <1E-300, 62% of all 
absorptive enterocytes, see Table S4). All other epithelial subtypes expressed ACE2 to a lesser 
extent, and variably co-expressed ACE2 with TMPRSS2 (see Table S4 for full statistics). 
 
Persistent viral RNA in rectal swabs has been detected in pediatric infection, even after negative 
nasopharyngeal tests (Xu et al., 2020). In an additional dataset consisting of endoscopic 
biopsies from the terminal ileum of a human pediatric cohort (n=13 donors, ranging in age 10-18 
years old) collected with 10X 3’ v2, we confirmed a large abundance of ACE2+ cells with 
selective expression within absorptive enterocytes (29.7% ACE2+, FDR-adjusted p=2.46E-100, 
Figure 3D-E, Table S5, STAR Methods). Furthermore, we identified a subset (888 cells, ~6.5% 
 
of all epithelial cells) that co-express both genes (Figure S2A-C). We performed differential 
expression testing and GO-term enrichment using these cells relative to matched non-
expressers to highlight putative biological functions enriched within them, such as metabolic 
processes and catalytic activity, and to identify shared phenotypes of ACE2+/TMPRSS2+ ileal 
cells across both human and NHP cohorts (Table S5). We speculate that viral targeting of these 
cells, taken from patients without overt clinical viral infection, may help explain intestinal 
symptoms. Finally, we compared ileal absorptive enterocytes from healthy NHPs and NHPs 
infected with Simian-Human Immunodeficiency Virus (SHIV) and then treated for 6 months with 
anti-retroviral therapy (animal and infection characteristics published in (Colonna et al., 2018), 
STAR Methods). We found significant upregulation of ACE2, STAT1, and IFI6 within the 
absorptive enterocytes of SHIV-infected animals (which maintain chronically elevated levels of 
IFN and ISGs) relative to uninfected controls (FDR-adjusted p = 1.3E-17, Figure S2D) (Deeks 
et al., 2017; Utay and Douek, 2016).  
 
Upper Airway Expression of Host Factors used by SARS-CoV-2 
To identify potential viral target cells in nasal and sinus tissue, two regions that are frequently 
primary sites of exposure for coronaviruses, we analyzed existing scRNA-seq datasets from the 
human upper airway (inferior turbinate and ethmoid sinus mucosa) across a spectrum of healthy 
donors and individuals with allergic inflammation due to chronic rhinosinusitis collected with 
Seq-Well v1 (CRS; Figure 4A; STAR Methods) (Ordovas-Montanes et al., 2018). We had 
previously noted a significantly-enriched IFN-dominated gene signature in inferior turbinate 
secretory epithelial cells from both healthy and CRS donors relative to CRS samples from the 
ethmoid sinus, which were significantly enriched for IL-4/IL-13 gene signatures (Giovannini-
Chami et al., 2012; Ordovas-Montanes et al., 2018). We speculate that these cells, taken from 
clinically non-virally infected patients, yet constantly exposed to environmental viruses, may 
provide one of the earliest locations for coronaviruses to infect before spreading to other 
tissues. When compared to all cell types recovered from surgically-resected mucosa, we 
observed significant enrichment of ACE2 expression in apical epithelial cells, and to a lesser 
extent, ciliated cells (1% of apical epithelial cells, FDR-adjusted p = 4.55E-6, n.s. in ciliated 
cells) (Figure 4B, Table S6). 
 
To better map putative SARS-CoV-2 targets among epithelial subsets, we employed a finer-
grained clustering method applied to both ethmoid sinus surgical specimens and scrapings from 
the inferior turbinate and ethmoid sinus (Figure 4C-F). Once again, we observed selective 
expression of ACE2 within a minority of cell types, with 1.3% of all secretory cells expressing 
ACE2 (Figure 4C, FDR-adjusted p-value = 0.00023), specifically sub-clusters 7 and 13, which 
represent two varieties of secretory epithelial cell (Figure 4C,F,G). Cluster 7 secretory cells are 
marked by S100P, LYPD2, PSCA, CEACAM5, STEAP4, encompass some MUC5AC goblet 
cells, and contain the most significantly enriched ACE2 and TMPRSS2 expression (4% express 
ACE2, FDR-adjusted p = 7.32E-28, 28% express TMPRSS2, FDR-adjusted p = 2.15E-132, 
Table S6). We next explicitly gated cells by their TMPRSS2 and ACE2 expression, identifying a 
rare subset that co-expresses both, the majority of which fall within the “Secretory Cluster 7” cell 
type (Figure 4E-F; 30 cells, ~0.3% of all upper airway secretory cells, 1.6% of goblet “Secretory 
Cluster 7”). These findings are aligned with concurrent work by the HCA Lung Biological 
Network on human nasal scRNA-seq data, which identified nasal secretory cells to be enriched 
for ACE2 and TMPRSS2 expression (Sungnak et al., 2020).  
 
Though we identified co-expression of ACE2 and TMPRSS2 in few airway cells overall, we 
detected ACE2 and TMPRSS2 single and double positive cells in over 20 donors and thus posit 
that these genes are enriched in secretory cells and not a product of individual patient-driven 
 
variability (Figure S3A). Inferior turbinate scrapings collected on Seq-Well S^3, which increases 
the resolution of lower-abundance transcripts relative to Seq-Well v1, revealed consistent and 
specific expression restricted to goblet secretory cells, but at a greater detection frequency in 
samples from the same donors (Figure S3B; ACE2+ v1 4.7% to S^3 9.8%; ACE2+/TMPRSS2+ 
from 1.9% v1 to 4% S^3) (Hughes et al., 2019). Using the gated ACE2+/TMPRSS2+ cells, we 
tested for differentially expressed genes compared to the remaining secretory epithelial cells 
(full results provided in Table S6). Notably, we observed significant upregulation of ADAR, 
GBP2, OAS1, JAK1 and DUOX2 (FDR adjusted, all p-value < 0.02) within ACE2+/TMPRSS2+ 
cells, potentially indicative of IFN-signaling (Figure 4G). Almost all “Secretory Cluster 7” cells 
were from inferior turbinate scrapings of healthy and allergically-inflamed individuals, with few 
cells from the ethmoid sinus tissue of patients with chronic rhinosinusitis without nasal polyps, 
and no cells detected in polyp tissue (Figure 4H). Gene Ontology analysis of enriched genes in 
double positive cells include processes related to intracellular cytoskeleton and macromolecular 
localization and catabolism, potentially involved in viral particle entry, packaging, and exocytosis 
(Fung and Liu, 2019).  
 
We next utilized IFN-inducible gene sets of relevance to human airway epithelial cells, which we 
derived from a prior study by performing differential expression on a published dataset where 
air-liquid interface cultures from primary human nasal epithelial cells were treated with IFNαA/D, 
IFNβ1a, IFNγ, IL-4 or IL-13 (Giovannini-Chami et al., 2012; Ordovas-Montanes et al., 2018). 
Using these gene lists, we scored the human nasal epithelial cells analyzed by scRNA-seq 
described in Figure 4C,F, and found significant concomitant upregulation of the IFNα-stimulated 
gene set within ACE2+/TMPRSS2+ secretory goblet cluster 7 (Figure 4I).  
 
Type I Interferon IFNα Drives ACE2 Expression in Primary Human Nasal Epithelial Cells 
The meta-analysis described above consistently identified an association between ACE2 
expression and canonical ISGs or components of the IFN-signaling pathway. This prompted us 
to investigate whether IFNs may play an active role in regulating ACE2 expression levels in 
specific target cell subsets, thus potentially allowing for a tissue-protective host response, or 
increased viral binding of SARS-CoV-2, through ACE2. Our initial literature search indicated that 
IFNγ and IL-4 downregulate the SARS-CoV receptor ACE2 in Vero E6 cells (African green 
monkey kidney epithelial cells, (de Lang et al., 2006), appearing to invalidate this hypothesis. 
Relatedly, in vitro stimulation of A549 cells, a commonly used cell line model for lung epithelia, 
with IFNα, IFNγ, and IFNα+IFNγ for 24 hours did not identify ACE2 as an ISG (Russell et al., 
2018). This is potentially explained by recent work which aimed to understand SARS-CoV-2 
receptor usage by performing screening studies within cell line models and found that A549 
cells did not express ACE2, and therefore represents a poor model to understand regulation of 
this gene (Letko et al., 2020). While conducting experiments to directly test the hypothesis that 
ACE2 is an ISG, we noted in our own gene lists used for scoring in (Ordovas-Montanes et al., 
2018) and in a supplementary extended table available with (Giovannini-Chami et al., 2012) that 
ACE2 was upregulated in gene lists following exposure to Type I IFN.  
 
We directly tested whether IFNα induces ACE2 in primary human upper airway epithelial cells in 
greater detail. We cultured human primary basal (stem and progenitors) epithelial cells to 
confluence and treated them with increasing doses (0.1 to 10 ng/mL) of IFNα2, IFNγ, IL-4, IL-
13, IL-17A, or IL-1β for 12 hours and then performed bulk RNA-seq (Figure S3C). Only IFNα2 
and IFNγ led to upregulation of ACE2 over the time period tested, with IFNα2 leading to greater 
and more significant upregulation over all doses tested relative to all other cytokines (Figure 
S3D, Wilcoxon test: IFNα FDR adjusted p = 4.1E-07; IFNγ p = 9.3E-03, Figure S3E-F, all 
statistical tests compared to 0 ng/mL dose). We confirmed substantial and dose-dependent 
 
induction of canonical members of the interferon response following IFNα2 and IFNγ (Figure 
S3G-H). Conversely, we found that IFNγ, relative to IFNα, induced potent upregulation of GBP5, 
a GTPase-like protein thought to act as a viral restriction factor through inhibiting furin-mediated 
protease activity, which could limit viral processing from infected cells, while IFNα2 more 
robustly induced IFITM1 (Figure S3I-K) (Braun and Sauter, 2019). 
 
To further extend and substantiate these findings, as above, we stimulated primary mouse 
tracheal basal cells, the commonly-used human bronchial cell line BEAS-2B, and upper airway 
basal cells from two human donors (Figure 5A-D). We confirmed appropriate induction of an 
IFN response in each cell type by performing differential expression testing between untreated 
cells and IFN-treated cells for each condition (Table S7). Within each cell type, stimulation with 
IFNα2, IFNγ, or IFNβ resulted in dose-dependent upregulation of canonical ISGs, including 
STAT1/Stat1, BST2/Bst2, XAF1/Xaf1, IFI35/Ifi35, MX1/Mx1, and GBP2/Gbp2. Notably, Ace2 
expression was not robustly induced in basal cells derived from healthy mouse trachea under 
any interferon stimulation condition (Figure 5A). The magnitude of ACE2 upregulation was 
diminished in BEAS-2B cells relative to our original findings in primary human upper airway 
epithelial cells, but reached statistical significance compared to the untreated condition following 
IFNγ exposure (Figure 5B). In primary basal cells derived from healthy nasal mucosa, we 
confirmed significant induction of ACE2 following IFNα2 stimulation, and to a lesser extent, 
following stimulation with IFNγ (IFNα2-stimulated: both Bonferroni-adjusted p<0.001, IFNγ-
stimulated: both Bonferroni-adjusted p<0.05, Figure 5C,D). Expression of ACE2 was 
significantly correlated with expression of STAT1 in all human cell types, with a larger effect size 
and correlation coefficient in primary human basal cells (Figure 5E-H). These experiments 
support a relationship between induction of the canonical IFN response, including key 
transcription factors, and transcriptional regulation of the ACE2 locus. Finally, among primary 
human samples, we confirmed dose-dependence of ACE2 upregulation following IFNα2 or IFNγ 
treatment, with significant induction of ACE2 following IFNα2 stimulation at concentrations as 
low as 0.1-0.5 ng/mL (Figure 5I-L). 
 
Next, using a publicly available resource (interferome.org) which hosts genomic and 
transcriptomic data from cells or tissues treated with IFN, we queried ACE2 expression within 
human and mouse cells, searching for datasets with a log2-fold-change of > 1 or < -1 compared 
to untreated samples, including all IFN Types (Rusinova et al., 2013). We recovered 21 
datasets spanning 8 distinct primary tissues or cell lines with non-trivial changes in ACE2 
expression following both Type I and Type II IFN treatment (Figure S4A). Substantial 
upregulation of ACE2 was observed in primary skin and primary bronchial cells treated with 
either Type I or Type II IFN (> 5-fold upregulation compared to internal untreated cells), in 
strong support of our in vitro data (Figures 5C,D,G-L; S3D-F). Immune cell types, such as CD4 
T cells and macrophages, were noticeably absent from datasets with a significant change in 
ACE2 expression following IFN stimulation, or were even found to downregulate ACE2 (e.g., 
primary CD4 T Cells + Type I IFN, Figure S4A, and in our analysis of scRNA-seq peripheral 
blood mononuclear cell data from (Butler et al., 2018); data not shown).  
 
As the majority of cells robustly upregulating ACE2 were epithelial, this observation potentially 
explains why previous analyses to define canonical ISGs within immune populations did not 
identify ACE2 as an induced gene. Further, using both TRANSFAC data hosted by the 
interferome database, as well as ChIP-seq data (provided by the ENCODE Factorbook 
repository), we find evidence for STAT1, STAT3, IRF8, and IRF1 binding sites within -1500-
+500 bp of the transcription start site of ACE2 (all in human studies, Figure S4B) (Gerstein et 
al., 2012; Matys et al., 2003; Wang et al., 2012; Wang et al., 2013). This finding is supportive of 
 
our current hypothesis that ACE2 represents a previously unappreciated ISG in epithelial cells 
within barrier tissues.  
 
Given minimal upregulation of Ace2 among primary mouse basal cells in vitro, we were curious 
as to whether Ace2 represented a murine ISG in vivo. We treated two mice intranasally with 
saline, and two mice intranasally with 10,000 units of IFNα (Guerrero-Plata et al., 2005). After 
12 hours, we isolated the nasal mucosa, consisting of both respiratory and olfactory epithelium, 
with underlying lamina propria, and performed scRNA-seq using Seq-Well S^3 (Figure S5A). 
We collected both tissue sites due to early reports of anosmia in COVID-19 (Lechien et al., 
2020). We recovered 11,358 single cells, including epithelial, stromal, neuronal, and immune 
cell types, generating the largest single-cell atlas of mouse respiratory and olfactory mucosa to 
date (Figures 6A; S5B). We annotated all 36 clusters, focusing our attention on epithelial cell 
clusters, as we noted enrichment for Ace2 and Tmprss2 within epithelial cell subsets, consistent 
with our human and NHP results (Table S8). Specifically, we found Ace2 enriched within 
olfactory epithelial gland cells, Muc5b+ Scgb1c1+ goblet cells, basal epithelial cells, and 
myofibroblasts/pericytes (Bonferroni-corrected p < 0.01, Figures 6B; S5B) (Brann et al., 2020; 
Dear et al., 1991; Montoro et al., 2018; Tepe et al., 2018). Notably, Furin was enriched within 
olfactory epithelial gland cells (Table S8). Next, we asked whether a 12-hour stimulation with 
IFNα would upregulate Ace2 in vivo. Focusing on basal epithelial cells, which contain the 
highest abundance of Ace2+ cells, we found that despite robust upregulation of canonical 
murine ISGs, Ace2 expression was only slightly elevated following IFNα treatment (Figures 6C-
D; S5C-D).  
 
This observation was supported by analysis of scRNA-seq data from 5,558 epithelial cells from 
the lungs of mice 3-6 days following intranasal infection with murine gamma herpesvirus-68 
(MHV68) (Figure S5E). Here, we found significant enrichment of Ace2+ cells within type II 
pneumocytes, in line with our data from NHP and human lungs (Figure S5F-G). We did not 
observe changes in Ace2 expression amongst viral-transcript positive cells or “bystander” type II 
pneumocytes (those without detectable cell-associated viral RNA in MHV68-infected animals), 
nor did we see significant alterations in Ace2+ cell abundance among MHV68-infected mice 
lacking the IFNγR (Figure S5H). These observations were in agreement with our in vitro murine 
basal cell assay (Figure 5A,E).  
 
Finally, we sought to validate our hypothesis that ACE2 is upregulated in human epithelial cells 
during upper airway viral infections which are known to induce a robust IFN response (Bailey et 
al., 2014; Everitt et al., 2012; Iwasaki and Pillai, 2014; Jewell et al., 2010; Russell et al., 2018; 
Steuerman et al., 2018). We re-analyzed a publicly available data set of RNA-seq from human 
lung explants isolated following surgical resection that were infected with influenza A virus ex 
vivo for 24 hours. Here, we found that ACE2 expression was significantly correlated with that of 
SFTPC, supporting our hypothesis that ACE2 is expressed within type II pneumocytes (Figures 
1C, 2C; S5I-J) (Matos et al., 2019). Furthermore, while the abundance of SFTPC was not 
significantly altered by influenza A virus infection, ACE2 expression was significantly 
upregulated following viral exposure (p = 0.0054, ratio paired t-test Figure S5K-L). This 
suggests that influenza A virus infection increases ACE2 expression. Nevertheless, these 
population-level analyses are not able to definitively resolve specific cell subsets of relevance, 
nor whether they are directly infected cells or bystanders of infection.  
 
In order to address these questions, we leveraged an ongoing scRNA-seq study of nasal 
washes from 18 individuals with confirmed influenza A virus or influenza B virus infection, or 
healthy controls collected with Seq-Well v1, which yielded 35,840 cells resolved into 17 distinct 
 
cell types (Figure 6E, STAR Methods) (Cao et al., 2020). We investigated the cell types with 
greatest enrichment for ACE2 and TMPRSS2 in non-infected controls, and with influenza A and 
B. Strikingly, ACE2 was most upregulated in samples from influenza virus infected individuals 
within bystander goblet or squamous cells not directly infected by virus (Figure 6F-G). ACE2+ 
TMPRSS2+ goblet cells during influenza infection exhibited enrichment for canonical ISGs such 
as the CXCL9/10/11 gene cluster, correspondence with ACE2+ TMPRSS2+ goblet cells in 
healthy and allergic nasal scrapings, and a shared overlap in ISGs including GBP2, ZNFX1, 
ADAR, and ACE2 (significantly-differentially expressed gene lists; Table S6). Together, our data 
suggest that ACE2 is an ISG in vitro and in vivo in human primary upper airway epithelial basal 
cells, but that the murine homolog Ace2 is not in airway epithelial basal cells or pulmonary 
epithelial cells in vitro or in vivo. Collectively, our findings suggest that careful considerations of 
animal and cellular models will be required for assessing therapeutic interventions targeting the 
IFN-system when studying ACE2/Ace2 associated biology. 
 
Finally, since our in vivo and in vitro work indicate that IFN may promote human cellular targets 
for SARS-CoV-2 infection in the human upper airway by inducing ACE2, we attempted to 
extend our transcriptomic data on IFN-driven expression of ACE2 to protein-level induction of 
ACE2. As testing of various commercially-available polyclonal antibody preparations found 
broad evidence for non-specific or inconclusive staining in histological immunofluorescent based 
readouts (data not shown), we assessed whether IFNγ-stimulated human bronchial air-liquid 
interface cultures induced ACE2 within 24 hours. Our results show that cells from one patient 
robustly induced ACE2 (+2.02x), cells from another mildly induced ACE2 (+1.21x) and two 
patient’s cells showed minor changes (+/- 1.12x) (Figure S5M). We provide a note of caution as 
these cells were derived from asthmatic patients, and the overall changes did not reach 
significance. Furthermore, we could not determine cell-surface localization of ACE2, but do note 
that these results align with our transcriptomic data.  
 
 
Discussion 
Here, we utilize scRNA-seq across various barrier tissues and model organisms to identify the 
potential initial cellular targets of SARS-CoV-2 infection. To review the data presented: 1) we 
find that expression of the cellular entry receptor for SARS-CoV-2, ACE2, is primarily restricted 
to type II pneumocytes in the lung, absorptive enterocytes within the gut, and goblet secretory 
cells of the nasal mucosa; 2) ACE2 and TMPRSS2 co-expression in respiratory tissues is 
consistently found only among a rare subset of epithelial cells; 3) we observe similarities in the 
cellular identities and frequencies of putative SARS-CoV-2 target cells across human and NHP 
cohorts; 4) we observe increased expression of ACE2 during SHIV and TB infection of NHPs, 
and HIV/TB coinfection and influenza infection of humans relative to matched controls, but 
caution that none of the datasets presented here were designed to answer this specific query. 
Specific targeting of these cell subsets has only been described for a handful of viruses, 
including: goblet cells by human adenovirus-5p and enterovirus 71, type II pneumocytes by 
H5N1 avian influenza, and absorptive enterocytes by rotavirus (Fleming et al., 2014; Good et 
al., 2019; Holly and Smith, 2018; Weinheimer et al., 2012).  
 
Additionally, we provide an overall note of caution when interpreting scRNA-seq data for low 
abundance transcripts like ACE2 and TMPRSS2 as detection inefficiencies may result in an 
underestimation of the actual frequencies of ACE2+ or ACE2+/TMPRSS2+ cells in a tissue. 
Moreover, the protein levels of each may differ from their mRNA abundances (Genshaft et al., 
2016; Jovanovic et al., 2015; Rabani et al., 2011; Shalek et al., 2013). We also present data 
sets separately, as each study differed in its methods of tissue processing and collection, which 
 
can influence the frequency of recovered cell subsets (STAR Methods). We provide Table S9 
as a summary of ACE2+ and ACE2+/TMPRSS2+ cells across various datasets. Moreover, we 
present Figure S6, which describes statistical modeling and power calculations underlying 
detection and dropout of ACE2, to help guide interpretation of these data. This includes an 
examination of the probability to detect a lowly-expressed transcript like ACE2 within a cell, as 
well as upper bound estimates on the percentage of positive cells within a cluster, considering 
the effects of transcript counts, sequencing depth, and cell numbers in these calculations 
(STAR Methods).  
 
Whether ACE2 and TMPRSS2 are required on the same cell, or soluble proteases can activate 
SARS-CoV-2 S-protein to invade ACE2-single positive cells, is an area of active inquiry 
(Coutard et al., 2020; Letko et al., 2020). Importantly, rapidly evolving literature has identified 
that SARS-CoV-2-S may have a furin cleavage site, leading to a broader set of host proteases 
that could mediate S-protein activation (Bugge et al., 2009; Coutard et al., 2020; Walls et al., 
2020). However, as an active S-protein has a finite lifetime to find a target cell membrane, the 
timing and cellular location of S-protein activation is key to consider. Activation events proximal 
to the plasma membrane have been shown to be most effective for SARS-CoV entry (Shulla et 
al., 2011).  
 
Our study finds that Type I IFNs, and to a lesser extent Type II IFNs, upregulate ACE2. This is 
based on several lines of evidence: 1) we identify a human goblet secretory cell subset in upper 
airway nasal epithelium enriched for ACE2 expression to have the highest IFNα-induced gene 
signature; 2) we find that IFNα, and to a lesser extent IFNβ or IFNγ, induced ACE2 expression 
in a published data set of air-liquid interface cultures derived from human nasal epithelial cells 
(Giovannini-Chami et al., 2012; Ordovas-Montanes et al., 2018); 3) we extend our search 
through the Interferome database (Rusinova et al., 2013) and find that, in epithelial barrier 
tissues, Type I IFNs upregulate ACE2 in multiple studies, especially in primary bronchial cells 
and keratinocytes (Rusinova et al., 2013); 4) we find two STAT1 binding sites in the promoter of 
ACE2; 5) in our unpublished atlas of SHIV-infected macaques, known to have elevated levels of 
chronic IFN signaling, we find ACE2 upregulation in absorptive enterocytes; 6) we directly 
provide evidence for IFNα, and to some extent IFNγ, inducing ACE2 expression in primary 
human upper airway basal cells; and, 7) influenza infection in humans, a known inducer of the 
IFN pathway, leads to increased ACE2 expression in goblet secretory cells of the nasal 
epithelium (Cao et al., 2020). 
 
Together, our own and publicly available data highlight that ACE2 may have been missed as a 
canonical ISG due to its notable absence in peripheral blood mononuclear cell data sets and in 
lung-derived transformed cell lines such as the A549 cell line (Butler et al., 2018; Letko et al., 
2020; Rusinova et al., 2013). Importantly, other groups have independently analyzed publicly 
available data sets, some referenced in our work, and observed ACE2’s behavior as an ISG 
(Wang and Cheng, 2020). Furthermore, we found weak IFN- or virally-driven induction of Ace2 
in murine cells and tissues. This highlights the importance of studying primary human epithelial 
cells, and the careful consideration of appropriately-selected gene lists and in vitro models of in 
vivo cellular systems for understanding human biology (Jonsdottir and Dijkman, 2016; Mead 
and Karp, 2019; Regev et al., 2017).  
 
As SARS-CoV-S leads to ACE2-receptor-mediated internalization, the host IFN response could 
thus promote the ability for SARS-CoV and SARS-CoV-2 to maintain cellular targets in 
neighboring human upper airway epithelial cells. Taken together along with a study of HCoV-
OC43, which co-opts IFN-inducible transmembrane (IFITM) 2 and IFITM3 to promote viral entry, 
this adds to the growing evidence that coronaviruses, as well as other viruses, have evolved to 
 
leverage features of the human IFN pathway (Fung and Liu, 2019; Mar et al., 2018; Zhao et al., 
2014). Whether Type I IFNs are net protective or detrimental to the host may depend on the 
stage of infection, cell subsets in question, the SARS viral clade (Channappanavar et al., 2016; 
Channappanavar et al., 2019; Channappanavar and Perlman, 2017; Davidson et al., 2015), and 
other factors such as co-infection, age, gender and co-morbidities, amongst others. 
Understanding the specific host restriction factors targeting SARS-CoV-2, and identifying 
specific drivers of these genes in the absence of ACE2 upregulation, may provide strategies to 
dissociate the dual roles of IFN in certain coronavirus infections. Whether IFNs upregulate 
ACE2 in putative target cell subsets in vivo will be of significant interest to define in future work 
once current COVID-19 related restrictions on basic scientific inquiry are lifted (Qian et al., 
2013).  
 
ACE2 is a central component of the renin-angiotensin system, which has emerged as a key 
regulator of sterile- or microbially-induced lung pathology (Imai et al., 2005). In brief, ACE 
cleaves angiotensin I to generate angiotensin II (Skeggs et al., 1980). Angiotensin II then acts to 
drive acute lung injury through various mechanisms, including increased vascular permeability 
(Imai et al., 2005). Levels of angiotensin II in humans and mice are elevated during influenza 
infection, and ACE2 exerts tissue-protective functions by reducing levels of angiotensin II (Zou 
et al., 2014). Binding of SARS-CoV-S to mouse ACE2 in vivo reduced ACE2 expression leading 
to acute acid aspiration-induced lung failure (Kuba et al., 2005). Depending on the questions 
asked in future work, there are mouse models available based on transgenic expression of 
human ACE2 (required for overt infectious pathology of SARS-CoV in mice), there are 
established NHP models available of SARS-CoV infection in M. fascicularis and C. aethiops, 
and early reports suggest symptomatic infection in M. mulatta and M. fascicularis models for 
SARS-CoV-2 (Bao et al., 2020; McCray et al., 2007; Munster et al., 2020; Rockx et al., 2020; 
Smits et al., 2011). For example, examining the efficacy of recombinant human ACE2 to act as 
a decoy receptor, or the impact of “ACE inhibitors” in patients with, or at risk for, COVID-19, will 
require careful experimentation in appropriate models together with well-controlled clinical trials 
(Hofmann et al., 2004; Monteil et al., 2020; Vaduganathan et al., 2020).  
 
IFN responses that induce ISGs are essential for host antiviral defense in mice, NHP and 
humans (Bailey et al., 2014; Dupuis et al., 2003; Everitt et al., 2012). Canonical ISGs function 
by directly restricting viruses and reducing burden (Schneider et al., 2014). More recently, 
disease tolerance to equivalent pathogen burden by factors that increase the ability of the host 
to tolerate tissue damage has been identified as part of a combined host defense strategy 
(Iwasaki et al., 2017; Iwasaki and Pillai, 2014; Medzhitov et al., 2012; Schneider and Ayres, 
2008). Disease tolerance factors in the lung include interleukin (IL)-22 and amphiregulin 
(Iwasaki et al., 2017). During acute infection in the respiratory system, ACE2 is critical for early 
tissue tolerance responses to respiratory infection, including H5N1 influenza (Huang et al., 
2014; Zou et al., 2014). However, our discovery that ACE2 is an ISG in human epithelial cells, 
along with SARS-CoV-2 utilizing host ACE2 to gain entry to cells, suggests that SARS-CoV and 
SARS-CoV-2 may exploit the ACE2-mediated tissue-protective response to provide further 
cellular targets for entry. This potential strategy employed by SARS-CoV-2 could present a 
unique challenge for the human host, and is distinct from HCoV-OC43 which targets the two 
restriction factors IFITM2 and IFITM3 (Zhao et al., 2014). Our study provides motivation to 
understand the specific role and balance of Type I and Type II IFNs, as well as Type III IFNs, in 
tissue protection during, and host restriction of, SARS-CoV-2 infection. Key experiments to 
understand ACE2 as an ISG in tissue protection or genuine tolerance will require the 
appropriate mouse, NHP, or other model in BSL3/4 facilities to execute SARS-CoV-2 viral 
infections and measure host tissue health along with viral loads. Further work will also be 
needed to understand how coinfections, as well as other host factors, may impact both the 
 
susceptibility to, and dynamics of, host-SARS-CoV-2 infection. Moreover, carefully controlled 
clinical trials will be essential to determine the overall effects of different IFNs (Prokunina-
Olsson et al., 2020). 
 
Together, we anticipate that comprehensive characterization of the putative cellular targets of 
SARS-CoV-2 will be critical to understand basic mechanisms of viral tropism and disease 
pathophysiology, inform differential susceptibility among vulnerable populations, and potentially 
suggest unanticipated targets for drug inhibitors of viral infection. The cellular targets we 
nominate will need to be confirmed by specific reagents for SARS-CoV-2, as done for SARS-
CoV (Ding et al., 2004). Furthermore, the transcriptional response to the virus will need to be 
rigorously characterized in appropriate in vitro and in vivo model systems (Blanco-Melo et al., 
2020). We provide gene lists associated with target cells in specific tissues and diseases to aid 
the community in understanding this emergent disease. A concurrent HCA Lung Biological 
Network study assessing ACE2 and TMPRSS2 across more tissues also identified enrichment 
in nasal goblet and ciliated cells (Sungnak et al., 2020). Other studies are considering additional 
tissues, covariates, such as age, sex, and co-infection state, and represent a large coordinated 
international effort to the ongoing crisis (Pinto et al., 2020). One study in particular identified 
upregulation of ACE2 by respiratory viruses and TMPRSS2 by IL-13 in a pediatric cohort, 
suggesting further links to how underlying allergic conditions or co-infections may modulate 
these two SARS-CoV-2 related host factors (Sajuthi et al., 2020). 
 
During the preparation of this manuscript, several papers have been posted to bioRxiv 
assessing patterns of ACE2+ and TMPRSS2+ cells in barrier tissues (Brann et al., 2020; 
Lukassen et al., 2020; Qi et al., 2020; WU et al., 2020; Zhang et al., 2020). At a high level, these 
studies are largely in agreement with our report. Furthermore, another study appeared on 
bioRxiv profiling bronchoalveolar lavage fluid from 3 severe and 3 mild COVID-19 patients, 
though they were unable to profile sufficient numbers of epithelial cells (Liao et al., 2020).  
 
Our study highlights the power of scRNA-seq datasets, both existing and novel, to derive 
hypotheses relevant to human disease which may differ from paradigms established using cell 
lines. Further work will be critical to determine how SARS-CoV-2 influences temporal dynamics 
of host responses at single-cell resolution and which host factors may impact this (Kazer et al., 
2020). Given the unappreciated complexities of host-pathogen interactions between humans 
and SARS-CoV-2, the best measures to combat this pandemic continue to be surveillance and 
avoidance – especially as a deep understanding of the full spectrum of resistance and tolerance 
mechanisms will require the concerted efforts of scientists around the globe (Amanat et al., 
2020; Chu et al., 2020; Hadfield et al., 2018). Here, we seek to share our initial findings and 
data so that other groups may build on this discovery of ACE2 as an ISG, and further consider 
the careful balance between tissue tolerance and viral infection required at the human airway 
epithelium. 
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Main Figure Titles and Legends 
 
Figure 1. Expression of ACE2 in Type II Pneumocytes in Healthy Lungs of Non-Human 
Primates 
A. Schematic of protocol for isolation of lung tissue at necropsy from healthy non-human 
primates (M. mulatta, n=3), creation of scRNA-seq libraries using Seq-Well v1, and 
computational pipeline to identify cell types using unbiased methods. UMAP projection of 
3,793 single cells, points colored by cell identity (see STAR Methods).  
B. UMAP projection as in A, points colored by detection of ACE2 (coronavirus receptor, 
top) or TMPRSS2 (coronavirus S-protein priming for entry, bottom). Black: RNA 
positive, blue: RNA negative. 
C. Dot plot of 2 defining genes for each cell-type (Table S1, Bonferroni adjusted p-value < 
0.001) and ACE2 and TMPRSS2. Dot size represents fraction of cells within that type 
expressing a given gene, and color intensity represents binned count-based expression 
level (log(scaled UMI+1)) amongst expressing cells. ACE2 is enriched in Type II 
Pneumocytes (6.7% expressing, Bonferroni adjusted p-value = 8.62E-33), as is 
TMPRSS2 (29.5% expressing, Bonferroni adjusted p-value = 8.73E-153). 3.8% of all 
Type II Pneumocytes co-express ACE2 and TMPRSS2 (Table S9). Red arrow: cell type 
with largest proportion of ACE2+/TMPRSS2+ cells. 
D. Genes expressed among ACE2+ and ACE2- Type II Pneumocytes. (SCDE package, 
Bonferroni adjusted p-value < 0.05 for IFNGR2, NT5DC1, ARL6IP1, TRIM27, full results: 
Table S1).  
See also Table S1 
 
Figure 2. Select Lung Epithelial Cells from Healthy, HIV-1 Infected, and Mycobacterium 
tuberculosis Infected Human Donors Co-Express ACE2 and TMPRSS2 
A. Schematic of protocol for isolation of human lung tissue from surgical excess, creation of 
single-cell RNA-seq libraries using Seq-Well S^3, and computational pipeline to identify 
cell types using unbiased methods. Right: UMAP projection of 18,915 cells across 8 
donors (n=3 TB+/HIV+; n=3 TB+; n=2 non-infected patients). Cells represented by 
points, colored according to cell type (see STAR Methods). 
B. UMAP projection as in A., points colored by detection of ACE2 (top) or TMPRSS2 
(bottom). Black: RNA positive, blue: RNA negative. 
C. Dot plot of 2 defining genes for each cell type (Bonferroni adjusted p-value < 0.001) and 
ACE2, and TMPRSS2; dot size represents fraction of cells within cell type expressing, 
and color intensity binned count-based expression level (log(scaled UMI+1)) amongst 
expressing cells. All cluster-defining genes are provided in Table S2). Red arrow: cell 
types with largest proportion of ACE2+/TMPRSS2+ cells. 
D. Volcano plot identifying significantly upregulated genes in ACE2+ TMPRSS2+ 
pneumocytes cells compared to all remaining pneumocytes. Red points represent genes 
with a Bonferroni-adjusted p-value < 0.05, and log2(fold change) > 1.5. Text highlighting 
specific genes, full list available in Table S2. 
E. Expression of ACE2 across human donors by HIV and TB status (p = 0.009 by likelihood 
ratio test). 
See also Table S2 
 
Figure 3. NHP and Human Ileal Absorptive Enterocytes Co-Express ACE2 and TMPRSS2 
A. Expression ACE2 across diverse tissues in healthy NHPs (n=3 animals, 52,858 cells). 
 
B. Schematic of protocol for isolation of NHP ileum (n=5) at necropsy for single-cell RNA-
seq using Seq-Well v1, and computational pipeline to identify cell types using unbiased 
methods. Right: UMAP projection of 4,515 cells colored by cell type. 
C. Dot plot of 2 defining genes for each cell type, with ACE2 and TMPRSS2. Dot size 
represents fraction of cells within cell type expressing, and color intensity binned count-
based expression level (log(scaled UMI+1)) amongst expressing cells. All cluster 
defining genes are provided in Table S4. Red arrow: cell type with largest proportion of 
ACE2+/TMPRSS2+ cells. 
D. Schematic of protocol for isolation of human ileum cells from endoscopic pinch biopsies 
in non-inflamed regions (n=13). Right: t-SNE plot generated from 13,689 epithelial cells 
selected from original dataset generated by 10x 3’ v2 (see Figure S2), colored by 
cellular subsets. 
E. Dot plot of 2 defining genes for each cell type, with ACE2 and TMPRSS2. Dot size 
represents fraction of cells within cell type expressing, and color intensity binned count-
based expression level (log(scaled UMI+1)) amongst expressing cells. All cluster 
defining genes are provided in Table S5. Red arrow: cell type with largest proportion of 
ACE2+/TMPRSS2+ cells. 
F. Expression of ACE2 (left) and TMPRSS2 (right) among all epithelial subsets from human 
donors. 
See also Figure S2, Table S4, Table S5 
 
Figure 4. Healthy and Allergic Inflamed Human Nasal Mucosa Co-Express ACE2 and 
TMPRSS2 in a Subset of Goblet Secretory Cells 
A. Schematic for sampling of n=12 ethmoid sinus surgical samples and n=9 inferior 
turbinate nasal scrapings to generate scRNA-seq libraries using Seq-Well v1. See 
(Ordovas-Montanes et al., 2018) 
B. Dot plot of all cell-types from ethmoid sinus-derived cells (n=6 non-polyp CRS samples, 
n=6 polyp CRS samples). 2 defining genes for each cell type, in addition to CDHR3 
(rhinovirus receptor), ACE2, TMPRSS2, and JAK1. Dot size represents fraction of cells 
within that type expressing, and color intensity represents binned count-based 
expression level (log(scaled UMI+1)) amongst expressing cells (see Table S6 for 
statistics by subset). Red arrow: cell types with largest proportion of ACE2+/TMPRSS2+ 
cells. 
C. Dot plot for 2 defining genes for each cell type identified from granular SNN clustering of 
epithelial cells (18,325 single cells) derived from both ethmoid sinus and inferior 
turbinate sampling (healthy inferior turbinate (3,681 cells, n= 3 samples), polyp-bearing 
patient inferior turbinate (1,370 cells, n= 4 samples), non-polyp ethmoid sinus surgical 
samples (5,928 cells, n= 6 samples), and polyp surgical and scraping samples directly 
from polyp in ethmoid sinus (7,346 cells, n = 8 samples). Red arrow: cell type with 
largest proportion of ACE2+/TMPRSS2+ cells. 
D. tSNE of 18,325 single epithelial cells from inferior turbinate and ethmoid sinus (omitting 
immune cells). Colored by cell types 3,152 basal, 3,089 differentiating, 8,840 secretory, 
1,105 ciliated, and 2,139 glandular cells. 
E. tSNE as in D, identifying epithelial cells co-expressing ACE2 and TMPRSS2 (30 cells, 
black points). 
F. tSNE as in D, colored by detailed cell types with higher granularity, as in C. 
G. Individual differentially expressed genes between ACE2+/TMPRSS2+ cells and all other 
secretory epithelial cells (see Table S6 for full gene list with statistics). Bonferroni 
adjusted likelihood-ratio test p < 0.02 for all genes displayed. 
 
H. Stacked bar plot of each subset of epithelial cells amongst all epithelial cells by donor 
(each bar) and sampling location (noted below graph) (unpaired t-test p < 0.00035 for 
Secretory Goblet 7 inferior turbinate vs. ethmoid sinus; see Table S6 for raw values).  
I. Violin plot of cell clusters in respiratory epithelial cells (from Figure 4C,F) ordered by 
average expression of IFNα-induced gene signatures, presented as a gene module 
score; non-normal distribution by Lilliefors test, Mann-Whitney U-test p=2.2E-16, 1.21 
effect size, IFNα signature for Secretory Goblet Cluster 7 vs. all epithelial cells. Arrow: 
cluster containing majority ACE2+/TMPRSS2+ cells. 
See also Figure S3, Table S6 
 
Figure 5. ACE2 is an Interferon-Stimulated gene in Primary Human Barrier Tissue 
Epithelial Cells  
A-D. Basal epithelial cells from distinct sources were cultured to confluence and treated with  
increasing doses (0.1 to 10 ng/mL) of IFNα2, IFNγ, IL-4, IL-17A, and/or IFNβ for 12 
hours  
and bulk RNA-seq analysis was performed. Expression of ACE2 (human) or Ace2 
(mouse) by cell type and stimulation condition. A. Primary mouse basal cells from 
tracheal epithelia, B. BEAS-2B Human Bronchial Cell Line, C. Primary human basal 
cells from nasal scraping, Donor 1, D. Primary human basal cells from nasal scraping, 
Donor 2. TP10K: transcripts per 10,000 reads. *** p < 0.001, ** p < 0.01, * p < 0.05, 
Bonferroni-corrected t-test compared to Untreated condition. 
E.-H. Co-expression of STAT1/Stat1 and ACE2/Ace2 by cell type. E. Primary mouse basal  
cells from tracheal epithelia, F. BEAS-2B Human Bronchial Cell Line, G. Primary human 
basal cells from nasal scraping, Donor 1, H. Primary human basal cells from nasal 
scraping, Donor 2. TP10K: transcripts per 10,000 reads. Statistical significance 
assessed by Spearman’s rank correlation.  
I.-L. Expression of ACE2 in primary human basal cells from nasal scrapings across a range  
of concentrations of IFNγ or IFNα2. I. IFNα2 dose response in Donor 1, p < 0.001 by 
one-way ANOVA. J. IFNγ dose response in Donor 1, p < 0.01 by one-way ANOVA. K. 
IFNα2 dose response in Donor 2, p < 0.001 by one-way ANOVA. L. IFNγ dose response 
in Donor 2, p < 0.001 by one-way ANOVA. TP10K: transcripts per 10,000 reads. *** p < 
0.001, ** p < 0.01, * p < 0.05, Bonferroni-corrected post-hoc testing compared to 0 
ng/mL condition. 
See also Figure S3, Figure S4, Table S7 
 
Figure 6. In vivo administration of Interferon in mice does not induce Ace2, and ACE2 is 
Induced in Goblet Secretory Cells during Human Influenza Infection  
A. UMAP of 11,358 single cells from mouse nasal epithelium (n=4).  
B. UMAP projection as in A., points colored by detection of Ace2 (coronavirus receptor  
homolog). Black: RNA positive, blue: RNA negative. 
C. Percent of Ace2+ cells by treatment condition (n=4 arrays per condition, 2 arrays per 
mouse). Black bars: Ace2+ positive cells; white bars: Ace2- cells. p = 0.4 by student’s t-
test).  
D. Heatmap of cell type defining genes (Trp63, Krt17), interferon-induced genes (Irf7, Stat1, 
Irf9, Oasl2), and Ace2 among Basal Epithelial Cells, separated by cells derived from 
saline-treated mice (left) and interferon-α treated mice. Statistical significance by 
likelihood ratio test with Bonferroni correction. Full list of differentially expressed genes in 
Table S8. 
E. Schematic for sampling cells derived from nasal washes of n=18 human donors with and  
 
without current influenza A or B infection for Seq-Well S^3 (35,840 single cells). See 
(Cao et al., 2020). 
F and G. ACE2 expression among Goblet Cells (F) and Squamous Cells (G) by infection  
status. Healthy Donor: cells from influenza negative donors (white); Bystander Cells: 
cells from influenza A (IAV) or B (IBV) infected donors, no intracellular viral RNA 
detected (black); Flu Viral RNA+ Cells: cells with detectable intracellular influenza A or B 
viral RNA (red). Statistical significance by Wilcoxon test with Bonferroni correction, n.s. 
for bystander vs. infected. 
See also Figure S5, Table S6, Table S8 
  
 
Supplemental Figure Titles and Legends 
 
Supplemental Figure 1. NHP Tuberculosis Infected Lung and Granuloma 
Related to Figures 1 and 2 
A. UMAP projection of epithelial cells (1,099 cells) colored by annotated cell type, tissue 
source, and gating as ACE2+/TMPRSS2+ cells. ACE2+/TMPRSS2+ cells comprise 11% 
of Ciliated cells, 16% of Club cells, 10% Type I Pneumocytes, and 22% Type II 
Pneumocytes. Data generated using Seq-Well S^3 (Table S3). 
B. Number of cells (left) and % (right) ACE2+/TMPRSS2+ cells by tissue source 
(granuloma vs. uninvolved lung) and cell type. Ciliated cells and Club cells were omitted 
from this analysis as we detected too few cells (< 7 total cells) belonging to these 
clusters in the granulomas. Statistical significance assessed by Fisher Exact Test (Table 
S3). 
C. Dot plot of top cluster defining genes for each epithelial cell type and ACE2 and 
TMPRSS2. Dot size represents fraction of cells expressing, and color intensity 
represents average log(normalized UMI + 1) among all cells in each group scaled 
between 0 and 1 by gene. ACE2 expression is enriched in Club cells (Bimodal test, 
Bonferroni corrected p < 0.001), Ciliated cells (p < 0.005), and Type I pneumocytes (p < 
0.001). TMPRSS2 expression is enriched in Type I pneumocytes (p < .001) and Ciliated 
cells (p < .001) (Table S3). 
D. Dot plot of genes differentially expressed between ACE2+/TMPRSS2+ epithelial cells vs. 
rest (Bimodal test, Bonferroni corrected p-value < 0.01, log fold change > 0.5) between 
Type II Pneumocyte ACE2+/TMPRSS2+ cells and other Type II pneumocytes. (Table 
S3, c = number of cells, n = number of animals). 
 
Supplemental Figure 2. Human and NHP Ileum 
Related to Figure 3 
A. Top: tSNE projection of all cells from healthy pediatric human ileum within a previously-
unpublished 10x 3’ v2 dataset (115,569 cells). Red: higher expression of ACE2 (left), 
TMPRSS2 (right). Bottom: Corresponding violin plots of expression values for ACE2 
(left) and TMPRSS2 (right). Solid line: epithelial cells. 
B. Co-expression of ACE2 and TMPRSS2 by epithelial cell subset. Number indicates % of 
ACE2+/TMPRSS2+ cells by cell subset. 
C. tSNE projection of 13,689 cells as in Figure 3D, cells colored by co-expression of ACE2 
and TMPRSS2 (red).  
D. Expression of ACE2 and canonical interferon-responsive genes among absorptive 
enterocytes from Healthy (n=2) and SHIV-infected, anti-retroviral treated animals (n=3). 
Bonferroni-adjusted p-values by Wilcoxon test (healthy: 510 cells, SHIV-infected: 636 
cells).  
 
Supplemental Figure 3. Nasal and Sinus Mucosa 
Related to Figures 4 and 5 
A. Expression of ACE2 and TMPRSS2 across donors. 
B. Enhanced capture of ACE2 mRNA with second strand synthesis protocol employed in 
Seq-Well S^3. Dot size represents fraction of cells expressing. 
C. Cultured human primary basal epithelial cells at confluence were treated with increasing 
doses (0.1 to 10ng/mL) of IFNα2, IFNγ, IL-4, IL-13, IL-17A, and IL-1B for 12 hours and 
bulk RNA-seq analysis was performed (Replicate experiment using Human Donor 1 as 
in Figure 5) 
 
D. ACE2 expression by stimulation condition. Wilcoxon test each cytokine combined doses 
vs. rest: IFNα  adjusted p = 4.1E-07; IFNγ adjusted p = 9.3E-03; all else n.s. *** p < 
0.001. 
E. ACE2 expression by IFNα2 dose. Bonferroni-corrected t-test compared to 0 ng/mL 
condition: *** p < 0.001, * p < 0.05. 
F. ACE2 expression by IFNγ dose. Bonferroni-corrected t-test compared to 0 ng/mL 
condition: *** p < 0.001, * p < 0.05. 
G. IFITM1 expression by IFNα2 dose. Bonferroni-corrected t-test compared to 0 ng/mL 
condition: *** p < 0.001. 
H. IFITM1 expression by IFNγ dose. Bonferroni-corrected t-test compared to 0 ng/mL 
condition: *** p < 0.001. 
I. GBP5 expression among cultured human primary basal epithelial cells. Wilcoxon test: 
IFNα vs. IFNγ adjusted p = 2.94E-07; IFNγ adjusted p = 9.3E-03. TP10K: transcripts per 
10,000 reads. *** p < 0.001. 
J. GBP5 expression by IFNα2 dose. Bonferroni-corrected t-test compared to 0 ng/mL 
condition: *** p < 0.001. 
K. GBP5 expression by IFNγ dose. Bonferroni-corrected t-test compared to 0 ng/mL 
condition: *** p < 0.001. 
 
 
Supplemental Figure 4. Published Studies of Epithelial Cells Following Interferon 
Treatment or Viral Exposure  
Related to Figure 5 
A. Fold change of ACE2 expression among human or mouse datasets following Type I or 
Type II interferon treatment compared to untreated control. Generated from publicly 
available microarray data curated at interferome.org. Includes all studies with abs(fold-
change) > 1.  
B. Location of transcription factors binding regions spanning -1500 bp to +500 bp from the 
transcription start site of ACE2 (human, top) or Ace2 (mouse, bottom). Generated from 
TRANSFAC data using the interferome.org database (Matys et al., 2003; Rusinova et 
al., 2013). 
 
Supplemental Figure 5. Mouse Nasal Epithelium Following Interferon-α Exposure 
Related to Figure 6 
A. Schematic: mice were exposed to 10,000 units of IFNα or saline by intranasal 
application (n=2 per group). After 12 hours, animals were sacrificed and nasal epithelium 
was dissected and dissociated for single-cell RNA-seq using Seq-Well S^3.  
B. Dot plot of 2 defining genes for each cell type, with Ace2, Tmprss2, and Cdhr3. Dot size 
represents fraction of cells within cell type expressing, and color intensity binned count-
based expression level (log(scaled UMI+1)) amongst expressing cells. All cluster 
defining genes are provided in Table S8. Red arrows: cell types with largest proportion 
of Ace2+ cells. Dendrogram (left) by person correlation over differentially expressed 
genes with Ward clustering.  
C. UMAP of Basal Epithelial Cells (380 cells) across 4 mice. Black: Saline-treated mouse; 
red: interferon-α treated.  
D. UMAP of Basal Epithelial Cells as in C, points colored by detection of Ace2. Black: RNA 
positive, blue: RNA negative (6.6% Ace2+, Bonferroni adjusted p = 1.1E-10 for Basal 
Epithelial Cell expression vs. all other cells). 
 
E. Schematic: wildtype (WT) and IFNγ-receptor knockout (IFNγR-/-) mice were infected 
intranasally with murine gamma-herpesvirus-68 (MHV68). Cells from whole lung were 
digested for scRNA-seq using Drop-seq (yielding 5,558 Epcam+ cells). 
F. Expression of Ace2 by epithelial cell type, wild type (WT) mice. Statistical significance by 
Wilcoxon rank sum test with Bonferroni correction. 
G. Expression of Ace2 among type II pneumocytes binned by infection status in WT mice. 
All pairwise comparisons non-significant (p > 0.05) by Wilcoxon rank sum test. 
H. Percent of Ace2+ cells by infection condition (uninfected, bystander cells in MHV68-
infected mouse, MHV68 RNA+ cells) and mouse genotype (WT, IFNγR -/-). Black bars: 
Ace2+ positive cells; white bars: Ace2- cells.  
I. Schematic of RNA-Seq data from (Matos et al., 2019) of human lung explants (n=5 
donors) exposed to influenza A virus (IAV, H3N2) at 24 hours post infection.  
J. Expression of SFTPC (surfactant protein C, a marker of type II pneumocytes) vs. ACE2 
among mock-infected lung explants. Statistical significance assessed by Pearson’s 
correlation, r = 0.93, p = 0.021. TPM: transcripts per million. 
K. SFTPC expression among matched donors following mock or IAV infection for 24 hours. 
Statistical significance assessed by ratio paired t-test, p = 0.86. 
L. ACE2 expression among matched donors following mock or IAV infection for 24 hours. 
Statistical significance assessed by ratio paired t-test, p = 0.0054. 
M. Western blot of fully-differentiated air-liquid interface cultures from bronchial cells 
derived from 4 human donors with asthma. Cells from each donor were treated with 10 
ng/mL IFNγ for 24 hours, and compared to a matched untreated condition. ACE2 protein: 
AF933 (R&D). Fold changes quantified for IFNγ treated vs. untreated for each patient 
donor following normalization to GAPDH. 
 
Supplemental Figure 6. Power Calculations and Statistical Modeling of ACE2 Capture and 
Dropout 
Related to STAR Methods 
A. Probability of capturing and transcribing at least 1 ACE2 cDNA molecule, as a function 
of the capture/reverse transcription efficiency for a single molecule and the number of 
ACE2 molecules expressed in an individual cell. Note that Drop-Seq provides a 
capture/transcription efficiency of approximately 11-13%, setting a floor on this 
parameter, and the experimental platforms used in this study are either equivalent or 
superior (Macosko et al., 2015). 
B. Distribution of ACE2 fractional abundance within individual cells’ cDNA libraries (i.e., 
ACE2 UMIs / total number of reads), across non-human primate lung and ileum cell 
populations (see Figures 1 and 3). Mean fractional abundance among ACE2+ lung cells 
= 5.0E-5; mean fractional abundance among ACE2+ ileum cells = 2.7E-4.  
C. Distribution of the number of reads within non-human primate lung and ileum cell 
populations (see Figures 1 and 3). Mean +/- SEM reads among all lung cells = 28,512 
+/- 344; ACE2+ lung cells = 28,553 +/- 2,988; all ileum cells = 14,864 +/- 288; ACE2+ 
ileum cells = 10,591 +/- 441.  
D. Probability of observing at least one transcript for a gene of interest (e.g., ACE2) within 
an individual cell, as a function of sequencing depth and the gene’s fractional abundance 
(i.e., ACE2 reads / all reads) within the cell’s cDNA library. Fractional abundance 
provides the probability that a single read corresponds to the gene of interest, and 
presented heatmap indicates the probability that at least one read in the total number of 
reads allocated to the cell (i.e., from 103 to 106) originates from the gene of interest. 
Mean read depths and ACE2 fractional abundances for each tissue produce a 93.7% 
probability of detecting at least 1 ACE2 read in ileum cells, and a 76.0% chance for lung 
 
cells. Outlined rectangles highlight the regimes where cells from lung (turquoise) and 
ileum (pink) samples typically lie.  
E. Number of ACE2+ cells within each cluster, as a function of average read depth for all 
cells in that cluster. Number of cells detected as ACE2+ is not correlated with read 
depth, even across relatively wide ranges of average read depths (Pearson’s r = -0.31, 
n.s.).  
F. Probability of observing a particular number of cells positive for a gene of interest within 
a cluster, as a function of number of cells in the cluster. Probabilities were calculated 
under a negative binomial distribution with parameter P = 0.063 (the proportion of 
ACE2+ cells among Type II pneumocytes presented in Figure 1; STAR Methods). The 
horizontal grey line indicates the arbitrary cut-off value of p = 0.05. 
G. Given a population of cells with a known proportion that are positive for a gene of 
interest, probability of observing no positive cells (i.e., false negative identification of the 
cluster; solid lines) and probability of observing at least one positive cell as a function of 
cluster size.  
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Supplemental Table 8. Statistics and Gene Lists Related to Figure 6 and Figure S5 (Mouse 
Nasal Epithelium) 
A. Cluster defining genes for cell types presented in Figure 6A 
B. Ace2 and Tmprss2 statistics by cell type 
C. Differentially expressed genes among Basal Epithelial Cells treated with Saline vs. 
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STAR Methods 
 
RESOURCE AVAILABILITY 
 
Lead Contact  
Further information and requests for resources and reagents should be directed to and will be 
fulfilled by Dr. Jose Ordovas-Montanes (jose.ordovas-montanes@childrens.harvard.edu). 
 
Materials Availability 
This study did not generate new unique reagents.  
 
Data and Code Availability 
In Table S9, we provide a guide to all datasets analyzed in this paper as well as links to each 
individual dataset for download with the main landing page here: 
https://singlecell.broadinstitute.org/single_cell?scpbr=the-alexandria-project. To download the 
data from the portal, follow the link to the visualization page, sign in a free account in the portal 
using a Google apps enabled email address, and select the ‘Download’ tab in the study. 
Downloadable datasets include both raw and normalized cell x gene matrices, as well as 
relevant metadata. These datasets  are additionally available here to facilitate downloading:  
https://drive.google.com/drive/folders/1bxCIqNeZ7wLuVOT16gphwj98_cc9KhrV?usp=sharing.  
We have also posted these cell x gene matrices to Chan Zuckerberg Initiative cellxgene 
(https://chanzuckerberg.github.io/cellxgene/posts/cellxgene_cziscience_com) and the Broad 
Institute Single Cell COVID-19 portal (https://singlecell.broadinstitute.org/single_cell/covid19) as 
leading community efforts. FASTQ files and cell x gene matrices for NHP and murine datasets, 
and cell x gene matrices for human data sets, are available at GEO GSE148829.  
 
In this same table, we further highlight four access types. 1. published data sets where 
everything is available (1 study); 2. unpublished data sets where everything is available (2 
studies, 19,670 new cells for download), 3. unpublished data sets where ACE2+ cell subsets, 
and the necessary subsets to contextualize those cells (i.e. epithelial cells for type II 
pneumocytes) are fully available (5 studies, 17,986 new cells for download); and, 4. those 
unpublished data sets where expression is shared for ACE2/TMPRSS2 (2 studies, 9,112 new 
cells). For those unpublished data sets where only specific subsets of cells or genes are 
available, full expression matrices are available upon request for COVID-19 related questions. 
 
All data included in the present study can be visualized using the following web viewer:  
https://singlecell.broadinstitute.org/single_cell?scpbr=the-alexandria-project.  
 
As we gain further insight and feedback from our own groups, collaborators, and investigators, 
we will continue to provide updates on our resource websites, including the utility of in vitro 
systems, such as organoids (Mead et al., 2018), for the study of SARS-CoV-2: 
http://shaleklab.com/resource/covid-19-resources/ and www.ordovas-montanes-
lab.com/resources. We also note that there are several ongoing efforts unified together through 
the HCA Lung Biological Network group that we will reference and to which we will link as they 
become available.  
 
No custom code was used to analyze these data and all methods and packages used are cited 
in the Method Details section. 
 
 
EXPERIMENTAL MODEL AND SUBJECT DETAILS 
 
Human Intestinal Biopsies 
For human intestinal biopsies from the terminal ileum, the subjects were enrolled on a multi-
center clinical study, which was approved by the Institutional Review Board at Boston Children’s 
Hospital (protocol number: IRB-P00030890). Full information related to subject 
age/developmental stage and sex found in metadata associated with provided raw datasets. 
 
Human Lungs, Surgical Excess 
Samples were obtained through indicated lung lobe resection or diagnostic procedures in 
collaboration with clinicians at the Department of Cardiothoracic Surgery at Inkosi Albert Luthuli 
Central Hospital in Durban, South Africa. Informed consent was obtained from each participant. 
The study protocol was approved by the University of KwaZulu-Natal Institutional Review Board 
(approval BE024/09). Full information related to subject age/developmental stage and sex found 
in metadata associated with provided raw datasets. 
 
Human Nasal Polyps and Scrapings 
For inferior turbinate nasal scrapings, polyp scrapings, and ethmoid sinus surgical tissue 
samples, the Partners HealthCare Institutional Review Board (Boston, Massachusetts), 
approved the study and all subjects provided written informed consent (Ordovas-Montanes et 
al., 2018). Full information related to subject age/developmental stage and sex found in 
metadata associated with provided raw datasets. 
 
Human Nasal Washes, Healthy and Influenza Infected 
The Institutional Review Board of the University of Massachusetts Medical School (Worcester, 
Massachusetts) approved the study and all subjects provided written informed consent.  
 
Cell Culture of Primary Basal Cells and Cell Lines 
Human basal cells from non-polyp surgical resections from ethmoid sinus, BEAS-2B cells 
(ATCC), or mouse tracheal basal cells were placed into culture at a number of 10,000 cells 
seeded at passage 3 and cultured at confluence in 96 well flat-bottom collagen-coated tissue 
culture plates (Corning 3596) for 48 hours in Pneumacult-Ex serum-free media (Stemcell 
Technologies). All cells were incubated at 37ºC and 5% CO2.  
 
Non-Human Primates (M. mulatta) 
Healthy and SHIV-infected non-human primate (M. mulatta) work was conducted at the 
Washington National Primate Research Center (WaNPRC), an AAALAC accredited program, in 
accordance with the regulations detailed in the U.S. Department of Agriculture Animal Welfare 
Act and in the Guide for the Care and Use of Laboratory Animals of the National Institutes of 
Health. It was approved by University of Washington Institutional Animal Care and Use 
Committee. Expanded cohort characteristics described previously (Colonna et al., 2018). Full 
information related to subject age/developmental stage and sex found in metadata associated 
with provided raw datasets. 
 
Non-Human Primates (M. fascicularis) 
Tissues from Mycobacterium tuberculosis-infected non-human primates (M. fascicularis) were 
conducted at the University of Pittsburgh School of Medicine, an AAALAC accredited program, 
in accordance with the regulations detailed in the U.S. Department of Agriculture Animal 
Welfare Act and in the Guide for the Care and Use of Laboratory Animals of the National 
Institutes of Health. Full information related to subject age/developmental stage and sex found 
in metadata associated with provided raw datasets. 
 
 
Mouse Nasal and Olfactory Epithelium and Tracheal Cells 
C57BL/6J mice purchased from Jackson laboratory (Bar Harbor, ME, USA) were maintained 
within Ragon Institute’s HPPF barrier facility and all experiments were conducted with 
institutional IACUC approval. In this study, mice were 8-10 weeks of age, representing male and 
female animals. 
 
Mouse Lungs, MHV68 Infection 
C57BL/6 mice were purchased from Charles River Laboratories (Sulzfeld, Germany). IFNγR−/− 
mice on C57BL/6 background (C57BL/6, IFNγR−/− B6.129S7-Ifngr1 tm1Agt/J) were originally 
obtained from the Jackson Laboratory (Bar Harbor, ME, USA) and subsequently bred and 
propagated under SPF conditions at the Helmholtz Zentrum München. Animals with different 
genotypes were kept in the same animal room for the time of the experiment including an 
adaptation period prior to the start of the experiment. All animal experiments were in compliance 
with the German Animal Welfare Act (German Federal Law §8 Abs. 1 TierSchG), and the 
protocols were approved by the local Animal Care and Use Committee. 
 
 
METHOD DETAILS 
 
Methods of Sample Collection and Tissue Preparation for Single-Cell RNA-Seq  
NHP Ileum, Jejunum, Colon, Liver, Tonsil, Thymus, and Lung Tissue 
Animals were perfused with 0.5 L of PBS/kg immediately following euthanasia, tissues were 
isolated and placed in RPMI + 10% FBS and kept on ice until dissociation. Tissue sections were 
digested by mincing and incubating with collagenase IV (Life Technologies) and DNAse I 
(Roche) at 37ºC for 1 hour with agitation. Digested tissue was passed through a 100 µm metal 
strainer, cells were pelleted by centrifugation at 300g, rinsed with RPMI + 10% FBS, counted, 
and prepared as a single cell suspension for scRNA-Seq using Seq-Well v1 (see below). 
 
NHP Lymphoid Organs, Bone Marrow, PBMCs 
All lymph nodes, spleen, and bone marrow were ground through a metal strainer, transferred to 
a conical in RPMI + 10% FBS, and pelleted by centrifugation at 400g x 10 minutes. LN-derived 
cells were resuspended in RPMI + 10% FBS, counted and prepared as a single cell suspension. 
Spleen, bone marrow, and PBMCs were subjected to ACK lysis for 10 minutes at room 
temperature, quenched with RPMI + 10% FBS.  PBMCs and bone marrow derived cells were 
purified over a ficoll gradient (GE Healthcare) by centrifuging at 400g for 20 minutes at room 
temperature with no brake. Cells were then resuspended in RPMI + 10% FBS, counted, and 
diluted for scRNA-seq using Seq-Well v1 (see below). 
 
NHP Tuberculosis Infected Lung and Granuloma  
Ten Mycobacterium tuberculosis infected (Martin et al., 2017) adult non-human primates 
(Macaca fascicularis) were included in this study. A piece of lung tissue (without any grossly 
visible pathology) and 4 individual TB lung granulomas per animal were excised at necropsy 
and enzymatically dissociated using the GentleMacs system (Tumor dissociation kit, human; 
Miltenyi Biotec). Single cell suspensions were resuspended in RPMI + 10% FBS, counted and 
diluted for scRNA-seq using Seq-Well S^3 (see below). 
 
Human Lung Tissue 
Surgical samples from diseased lung tissue (n=3 TB+/HIV+; n=3 TB+; n=2 non-infected 
patients) were processed as described in (Ardain et al., 2019). Briefly, each sample was 
 
collected into cold RP-10 (RPMI (Sigma-Aldrich) + 10% FBS), minced, and incubated for 25-30 
minutes at 37ºC with digestion buffer containing collagenase D (Sigma-Aldrich), DNAse I 
(Sigma-Aldrich) in RPMI 1640 (Sigma-Aldrich) with 10% FBS (Hyclone). Following incubation, 
samples were homogenized using a GentleMACS, filtered using a 70 µm metal strainer, and 
pelleted by centrifugation at 400g for 5 minutes. After obtaining the pellet, cells were 
resuspended in RP-10, passed through another 70µm strainer (Corning), stained with trypan 
blue, and then counted and diluted for scRNA-Seq using Seq-Well S^3 (see below). 
 
Human Ileum 
Single-cell suspensions were collected from biopsies as described (Smillie et al., 2019). Briefly, 
biopsies were rinsed in cold PBS, the epithelial layer was separated from the underlying lamina 
propria by end over end rotation for 15 minutes. The lamina propria and epithelial fractions were 
digested separately, using Liberase TM (Roche) and DNase I (Roche) for the lamina propria, 
and TrypLE (ThermoFisher) for the epithelial fraction. Following digestion, cells were pelleted by 
centrifugation, subjected to ACK lysis for 3 minutes, and filtered through a 40 µm strainer. 
Following centrifugation, the cells were counted and prepared as a single cell suspension for 
scRNA-seq using 10X 3’ v2 (10X Genomics). 
 
Nasal Mucosa and Nasal Scrapings 
Surgical samples from ethmoid sinus and nasal scraping of the inferior turbinate were 
processed as described (Ordovas-Montanes et al., 2018). Briefly, each sample was collected 
into cold RPMI (Corning), minced and incubated for 30 minutes (15 minutes for nasal scrapings) 
at 37ºC with digestion buffer containing collagenase IV (Worthington), DNAse I (Roche) in RPMI 
with 10% FBS. Samples were triturated and digestion quenched with EDTA. Cells were filtered 
using a 70 µm metal strainer and pelleted by centrifugation at 500g, rinsed with PBS, and 
subjected to red blood cell (RBC) lysis using ACK buffer (ThermoFisher) for 3 minutes on ice, 
and finally pelleted prepared as a single cell suspension for scRNA-seq using Seq-Well v1 or 
S^3 (see below). 
 
Interferon Treatment of Mouse Nasal Mucosa 
Mice received either 200ng of IFNα (Biolegend 752802) or saline intranasally (each group n=2 
mice), and were sacrificed 12 hours later. Respiratory and olfactory mucosa were isolated as in 
(Davidson et al., 2004; Dunston et al., 2013). Briefly, using surgical tools under a dissecting 
microscope, the skull bones surrounding the nasal tissue of skinned mouse heads were 
removed. The respiratory and olfactory mucosa were collected in RPMI media with 10% FBS. 
Cells were digested in media containing Liberase TM (Roche) and DNase I (Roche) for 30 
minutes at 37ºC with agitation. Cells were filtered using a 70 µm strainer, washed with EDTA-
containing media to quench enzymatic digestion, and pelleted by centrifugation. RBCs were 
lysed using ACK buffer (ThermoFisher) for 2 minutes, cells were again pelleted, counted, and 
prepared as a diluted single cell suspension for scRNA-seq using Seq-Well S^3. 
 
MHV68 Infected Mouse Lung 
Mice were housed in individually ventilated cages during the MHV68 infection period. MHV68 
stocks were grown and quantified by plaque assay as previously described (Adler et al., 2000). 
Mice were infected intranasally (i.n.) with 5 × 10*4 plaque forming units of MHV68 diluted in 
PBS in a total volume of 30 µl. Prior to i.n. infection, mice were anesthetized with 
medetomidine–midazolam–fentanyl. At the predetermined time points, mice were sacrificed by 
cervical dislocation and lung tissue was processed for subsequent experiments. All lobes were 
removed, minced and transferred for mild enzymatic digestion for 20‐30 min at 37°C in an 
enzymatic mix containing Dispase (50 caseinolytic U/ml), Collagenase (2 mg/ml), Elastase (1 
mg/ml), and DNase I (30 µg/ml). Single cells were harvested by straining the digested tissue 
 
suspension through a 70µm strainer. After centrifugation at 300 x g for 5 minutes, single cells 
were counted, and prepared as a single cell suspension. For Drop-seq, cells were aliquoted in 
PBS supplemented with 0.04% of bovine serum albumin at a final concentration of 100 cells/µl. 
 
Nasal Washes during Influenza Infection 
Nasal washes were obtained from adult healthy controls and from adults with diagnosis of acute 
influenza A or B by rapid antigen test (Flu A or B antigen, direct fluorescence antigen test) 
and/or by respiratory virus panel (PCR testing for influenza A, influenza A H1, influenza A H3, 
influenza B, adenovirus, metapneumovirus, respiratory syncytial virus A, respiratory syncytial 
virus B, rhino/enterovirus, parainfluenza 1, parainfluenza 2, parainfluenza 3), who show 
symptoms up to seven days (Cao et al., 2020). Samples were obtained by irrigation of each 
naris with up to 10 mL of saline, and collected in a single container. The sample was then 
transported to the research laboratory for processing. Upon receipt, the sample was 
immediately stored on ice and 10 mL cell growth media (DMEM or RPMI1640 with 10% fetal 
bovine serum) was added. The material was strained using a 40 µm nylon cell strainer (Corning) 
into a 50 mL centrifuge tube. Cells were pelleted at 1300 rpm for 10 min at 4°C. All but 1 mL of 
supernatant was discarded, the pellet resuspended in the remaining 1 mL of supernatant, and 
material was transferred to an Eppendorf tube and pelleted at 2000 rpm for 5 min. If the pellet 
contained visible blood, 200 µL of RBC lysis solution (ACK buffer, Thermo Fisher) was added to 
resuspend the pellet and incubated at room temperature for 2 min, after which 1 mL of cell 
media was added, and the cells were pelleted at 2000 rpm for 5 min. The final pellet was 
resuspended in up to 1 mL of media and quantified before performing scRNA-seq with Seq-Well 
v1. 
 
 
Methods to Generate Single-Cell and Bulk RNA-seq Libraries 
Seq-Well v1 
Seq-Well was performed as described (Gierahn et al., 2017). Single cells were diluted to 15,000 
cells in 200 µL RPMI + 10% FBS and deposited onto a pre-functionalized PDMS array. 15,000 
cells were deposited onto the top of each PDMS array and let settle by gravity into distinct wells. 
The array was gently washed with PBS, and sealed using a functionalized polycarbonate 
membrane. Seq-Well arrays were sealed in a dry 37ºC oven for 40 minutes, and submerged in 
a lysis buffer containing guanidium thiocyanate (Sigma), EDTA, 1% beta-mercaptoethanol and 
sarkosyl (Sigma) for 20 minutes at room temperature. Arrays were transferred to hybridization 
buffer containing NaCl (Fisher Scientific) and agitated for 40 minutes at room temperature, 
mRNA capture beads with mRNA hybridized were collected from each Seq-Well array, and 
beads were resuspended in a master mix for reverse transcription containing Maxima H Minus 
Reverse Transcriptase and buffer, dNTPs, RNase inhibitor, a 5’ template switch oligonucleotide, 
and PEG for 30 minutes at room temperature, and overnight at 52ºC with end-over-end rotation. 
Exonuclease digestion and PCR were carried out as described. Post-whole transcriptome 
amplification workup involved AMPure XP SPRI bead cleanup occurred at a 0.6 x volume ratio, 
followed by 0.8x. Library size was analyzed using an Agilent Tapestation hsD5000 kit, 
confirming the expected peak at ~1000 bp, and absence of smaller peaks corresponding to 
primer. Libraries were quantified using Qubit High-Sensitivity DNA kit and prepared for Illumina 
sequencing using Nextera XT DNA Sample Preparation kit using 900 pg of cDNA library as 
input to tagmentation reactions. Amplified final libraries were purified twice with AMPure XP 
SPRI beads as before, with a volume ratio of 0.6x followed by 0.8x. Libraries from 2-3 Seq-Well 
arrays were pooled and sequenced together using a NextSeq 500/550 High Output v2 kit (75 
cycles) using a paired end read structure with custom read 1 primer: read 1: 20 bases, read 2: 
50 bases, read 1 index: 8 bases. 
 
 
Seq-Well S^3 
Seq-Well S^3 modified the following protocol steps from v1, above (Hughes et al., 2019). First, 
hybridization buffer was supplanted with 8% (v/v) polyethylene glycol (PEG, Sigma). Second, 
after exonuclease digestion, bead-associated cDNA was denatured for 5 minutes in 0.2 mM 
NaOH with end over end rotation. Next, beads were washed with TE + 0.01% tween-20, and 
second strand synthesis was carried out by resuspending beads in a master mix containing 
Klenow Fragment (NEB), dNTPs, PEG, and the dN-SMRT oligonucleotide to enable random 
priming off of the beads. 
 
10X v2 3’ 
Single cells were loaded onto 3’ library chips as per the manufacturers protocol for Chromium 
Single Cell 3’ Library (v2) (10X Genomics). Each biopsy was sequenced on two channels of the 
10X Chromium Single Cell Platform, one for the epithelial fraction and the other for the lamina 
propria fraction in order to recover sufficient numbers of epithelial and lamina propria cells for 
downstream analyses. An input of 6,000 single cells was added to each channel with a recovery 
rate of approximately 2,000 cells. 
 
Drop-seq 
Drop-seq experiments were performed according to the original protocol (Macosko et al., 2015). 
Briefly, single cells (100/µl) were co‐encapsulated in droplets with barcoded beads (120/µl, 
ChemGenes) at rates of 4000 µl/hr. Droplet emulsions were collected for 10‐20 min/each prior 
to droplet breakage by perfluorooctanol (Sigma‐Aldrich). After breakage, beads were harvested 
and the hybridized mRNA transcripts reverse transcribed (Maxima RT, Thermo Fisher). 
Exonuclease digestion and PCR were carried out as described (12 PCR cycles). For each 
sample, 1 ng of pre‐amplified cDNA from an estimated 1000 cells was tagmented by Nextera 
XT (Illumina) with a custom P5‐primer (Integrated DNA Technologies). Single‐cell libraries were 
sequenced in a 100 bp paired‐end run on the Illumina HiSeq4000. 
 
Smart-Seq2 for Bulk RNA-Seq 
Population RNA-seq was performed as described (Ordovas-Montanes et al., 2018; Trombetta et 
al., 2014). Briefly, RNA from population lysates was purified using AMPure RNA Clean Spri 
beads (Beckman Coulter) at a 2.2x volume ratio, and mixed with oligo-dT primer, dNTPs (NEB), 
and RNase inhibitor (Fisher Scientific) at 72ºC for 3 minutes on a thermal cycler to anneal the 3’ 
primer to polyadenylated mRNA. Reverse transcription was carried out in a master mix of 
Maxima RNaseH-minus RT enzyme and buffer (Fisher Scientific), MgCl2 (Sigma), Betaine 
(Sigma), RNase inhibitor, and a 5’ template switch oligonucleotide, and PCR was carried out 
using KAPA HiFi HotStart ReadyMix (Kapa Biosystems) and IS PCR primer and amplified for 18 
cycles. Libraries were purified using AMPure XP SPRI beads at a volume ratio of 0.8x followed 
by 0.9x. Library size was assessed using a High-Sensitivity DNA chip (Agilent Bioanalyzer), 
confirming the expected size distribution of ~1,000-2,000 bp. Tagmentation reactions were 
carried out with the Nextera XT DNA Sample Preparation Kit (Illumina) using 250 pg of cDNA 
per single cell as input, with modified manufacturer’s instructions as described. Libraries were 
purified twice with AMPure XP SPRI beads at a volume ratio of 0.9x, size distribution assessed 
using a High Sensitivity DNA chip (Agilent Bioanalyzer) and Qubit High-Sensitivity DNA kit 
(Invitrogen). Libraries were pooled and sequenced using NextSeq500/550 High Output v2 kits 
(75 cycles, Illumina) using 30-30 paired end sequencing with 8-mer dual indexing.  
 
Human and Mouse Basal Cell Cytokine Stimulation 
 
Data represented in Figure 5A-L: Cytokines were added for 12 hours overnight at increasing 
doses (0, 0.1 ,0.5, 1, 2, 5, 10 ng/mL) of IL-4 (human: Biolegend 574002), IL-17A (human: 
Biolegend 570502), IFNγ (human: Biolegend 570202; mouse: Peprotech 315-05), IFNα (human: 
Biolegend 592702; mouse: Biolegend 752802), or IFNβ (mouse: R&D Systems 8234-MB-010). 
Each condition was run as a biological triplicate. Data represented in Figure S3C-K: cytokines 
were added for 12 hours overnight at increasing doses (0, 0.1, 0.5, 1, 5, 10 ng/mL) of human IL-
4 (Biolegend 574004), IL-13 (Biolegend 571104), IFNα (Biolegend 592704), IFNγ (Biolegend 
570204), IL-17A (Biolegend 570504), or IL-1β (Biolegend 579404) (each condition run as a 
biological quadruplicate). All populations were lysed in 50 µL lysis buffer (RLT + 1% BME, 
Qiagen and Sigma, respectively) and snap frozen on dry ice. Bulk RNA-seq was performed as 
described previously and summarized above (Ordovas-Montanes et al., 2018). Populations 
were sequenced to an average +/- SEM read depth of 3.95 +/- 0.11 million reads per sample, 
with an average +/- SEM alignment percentage to either hg19 or mm10 reference 
transcriptomes of 71 +/- 0.3%. All samples met quality thresholds regarding genomic and 
transcriptomic alignment. 
 
Western blot for human ACE2  
Established air-liquid interface cultures from bronchial brushings of four asthmatic patients were 
treated with 10ng/µL of human IFNγ for 24 hours. Protein lysates were prepared, and anti-ACE2 
human antibody (AF933 R&D goat polyclonal) was used to probe for ACE2 by Western blot. 
Bands were normalized to GAPDH as loading control, and fold change was computed based on 
normalized ACE2 values.     
 
 
QUANTIFICATION AND STATISTICAL ANALYSIS 
 
Non-Human Primate Lung and Ileum 
Libraries corresponding to 7 animals (variable number of tissues per animal) were sequenced 
using Illumina NextSeq. Reads were aligned to the M. mulatta genome assembly 8.0.1 
annotation version 102 and processed according to the Drop-Seq Computational Protocol v2.0 
(https://github.com/broadinstitute/Drop-seq). Data was normalized and scaled using the Seurat 
R package v2.3.4 (https://github.com/satija.lab/seurat): transforming the data to loge(UMI+1) 
and applying a scale factor of 10,000. To identify major axes of variation within our data, we first 
examined only highly-variable genes across all cells, yielding approximately 1,000-3,000 
variable genes with average expression > 0.1 log-normalized UMI across all cells. An 
approximate principal component analysis was applied to the cells to generate 100 principal 
components (PCs). Using the JackStraw function within Seurat, we identified significant PCs to 
be used for subsequent clustering and further dimensionality reduction. For 2D visualization and 
cell type clustering, we used a Uniform Manifold Approximation and Projection (UMAP) 
dimensionality reduction technique (https://github.com/lmcinnes/umap) with “min_dist” set to 0.5 
and “n_neighbors” set to 30. To identify clusters of transcriptionally-similar cells, we employed 
unsupervised clustering as described above using the FindClusters tool within the Seurat R 
package with default parameters and k.param set to 10 and resolution set to 0.5. Each cluster 
was sub-clustered to identify more granular cell types, requiring each cell type to express >25 
significantly upregulated genes by differential expression test (FindMarkers implemented in 
Seurat, setting “test.use” to “bimod”, Bonferroni-adjusted p-value cutoff < 0.001). Differential 
expression tests between cells from ACE2+ vs. ACE2- Type II Pneumocytes were conducted 
using the SCDE R package with default parameters (Kharchenko et al., 2014). Expression data 
for epithelial cells and enterocytes included in this dataset can be visualized and downloaded 
 
here: https://singlecell.broadinstitute.org/single_cell/study/SCP807?scpbr=the-alexandria-
project#study-summary.  
 
Human Lung Tissue  
Libraries corresponding to 8 donors were sequenced using Illumina NextSeq. Reads were 
aligned to the hg19 genome assembly and processed according to the Drop-Seq Computational 
Protocol v2.0 (https://github.com/broadinstitute/Drop-seq). Data was normalized and scaled 
using the Seurat R package v3.1.0 (https://github.com/satija.lab/seurat), transforming the data 
to loge(UMI+1) and applying a scale factor of 10,000. For each array, we assessed the quality of 
constructed libraries by examining the distribution of reads, genes and transcripts per cell. 
Variable gene selection, principal components analysis, and selection of significant principal 
components was performed as above. We visualized our results in a two-dimensional space 
using UMAP (https://github.com/lmcinnes/umap), and annotated each cluster based on the 
identification of highly expressed genes. To further characterize substructure within cell types 
(for example, T cells), we performed dimensionality reduction (PCA) and clustering over those 
cells alone. Sub-clusters (i.e., clusters within broad cell type classifications) were annotated by 
cross-referencing cluster-defining genes with curated gene lists and online databases (SaVanT 
(http://newpathways.mcdb.ucla.edu/savant-dev/)  and GSEA/MsigDB (https://www.gsea-
msigdb.org/gsea/msigdb/index.jsp). Proliferating cells from the human lung (Figure 2C) express 
high levels of mitotic markers, such as MKI67, and represent primarily T cells (CD3D, CD3E), B 
cells/antibody-secreting cells (IGJ, MZB1, IGHG1), and myeloid cells (CD14, APOE) and 
represent a composite cell cluster. Differential expression analysis between ACE2+ TMPRSS2+ 
and negative type II pneumocytes was performed in Seurat using a likelihood-ratio test 
(FindMarkers implemented in Seurat, setting “test.use” to bimod). Expression data for epithelial 
cells included in this dataset can be visualized and downloaded here: 
https://singlecell.broadinstitute.org/single_cell/study/SCP814?scpbr=the-alexandria-
project#study-summary. 
 
Human Ileum 
Libraries corresponding to 13 donors were sequenced using Illumina NovaSeq S2 with a Read 
1 26bp, Read 2 91bp, Index 1 8bp configuration before reads were aligned to GRCh38. Each 
sample was filtered individually for low quality cells and genes by analyzing distributions of 
reads, transcripts, percent reads mapped to mitochondrial genes, and complexity per cell, then 
merged as an outer join to create a single dataset. Clustering and differential expression tests 
were processed using Seurat v3.1.0 (https://github.com/satija.lab/seurat). Normalization and 
variable gene selection was processed with SCTransform 
(https://github.com/ChristophH/sctransform). Clustering for major cell types was performed 
using Louvain clustering on dimensionally reduced PCA space with resolution set via grid 
search optimizing for maximum average silhouette score. Due to the scale of the dataset, a 
randomized subsampling from across the dataset was used to calculate the silhouette score. 
We annotated clusters based on highly expressed genes, then sub-clusters were characterized 
by performing PCA dimensionality reduction and clustering over those cells alone, and 
annotated based on highly expressed genes found via one-vs-rest differential expression test 
(Wilcoxon) within the major cell type. Differential expression analysis between 
ACE2+/TMPRSS2+ and negative epithelial cells was performed in Seurat using a Wilcoxon test 
and Bonferroni p-value correction. Expression data for epithelial cells included in this dataset 
can be visualized and downloaded here: 
https://singlecell.broadinstitute.org/single_cell/study/SCP812?scpbr=the-alexandria-
project#study-summary. 
 
 
Human Adult Nasal Mucosa 
Sample processing, sequencing, and analysis was performed as in (Ordovas-Montanes et al., 
2018). Briefly, scRNA-seq cell suspensions were freshly processed using Seq-Well v1 and 
Seurat v2.3.4 was utilized for computational analyses presented here (Butler et al., 2018; Satija 
et al., 2015). Cell by gene matrix and R code for initialization of object available to download as 
Supplementary Data and Supplementary Tables here https://www.nature.com/articles/s41586-
018-0449-8 and here: 
http://shaleklab.com/resource/mapping-allergic-inflammation/? and visualized here: 
https://singlecell.broadinstitute.org/single_cell/study/SCP253?scpbr=the-alexandria-
project#study-summary. Scores for various cytokines acting on human airway epithelial cells 
were calculated based on gene lists derived for (Ordovas-Montanes et al., 2018), calculated 
using AddModuleScore function Seurat, and effect size calculated by Cohen’s d, as previously 
reported.  
 
Granulomatous Tissue from Mycobacterium Tuberculosis Infected NHPs 
Libraries corresponding to 10 animals (variable number of tissues/animal) were sequenced 
using Illumina NovaSeq S2. Data was aligned using the Dropseq-tools pipeline on Terra 
(app.terra.bio) to M. fascicularis reference genome assembly 5, annotation version 101. 
Clustering was performed using Leiden clustering in the Scanpy (scanpy.readthedocs.io) 
package (Wolf et al., 2018). Cell type labels were assigned using known marker genes. In this 
analysis, we include all epithelial cell subsets (secretory, multiciliated, type II pneumocytes, and 
type I pneumocytes) from all samples. Differential expression between ACE2+/TMPRSS2+ cells 
and other cells of the matched cell subtype (e.g. Secretory Cells) were performed using 
Wilcoxon rank-sum tests within each cell subtype and filtered on Benjamini-Hochberg-corrected 
p-value < 0.05. Expression data for epithelial cells included in this dataset can be visualized and 
downloaded here: 
https://singlecell.broadinstitute.org/single_cell/study/SCP806?scpbr=the-alexandria-
project#study-summary. 
 
Basal Cell Cytokine Stimulation 
Libraries corresponding to 279 populations were sequenced using Illumina NextSeq. Reads 
were aligned to the hg19 or mm10 genome assembly using the cumulus platform 
https://cumulus-doc.readthedocs.io/en/0.12.0/smart_seq_2.html and output as TPM using 
RSEM v1.3.2. Populations were transformed to transcripts per 10K reads and log2(1+TP10K) 
transformed. ACE2 expression by stimulation condition and dose were assessed using one-way 
ANOVA with post hoc testing using a Bonferroni correction. Plots were generated using ggplot2, 
and transcriptome-wide differential expression was calculated using the Seurat R package 
v3.1.0 (https://github.com/satija.lab/seurat), function FindMarkers with test.use=”bimod”. 
Expression data can be visualized and downloaded here:  
https://singlecell.broadinstitute.org/single_cell/study/SCP822?scpbr=the-alexandria-project. 
 
Interferon Treatment of Mouse Nasal Mucosa 
Libraries corresponding to 4 mice, with 2 Seq-Well arrays per mouse were sequenced using 
Illumina NextSeq as described (Gierahn et al., 2017; Hughes et al., 2019). Reads were aligned 
to the mm10 genome and processed according to the Drop-Seq Computational Protocol v2.0 
(https://github.com/broadinstitute/Drop-seq). Data was normalized and scaled using the Seurat 
R package v2.3.4 (https://github.com/satija.lab/seurat): transforming the data to loge(UMI+1) 
and applying a scale factor of 10,000. Cells with fewer than 1000 UMIs and 500 unique genes 
were removed. To identify major axes of variation within our data, we first examined only highly-
 
variable genes across all cells, yielding approximately 5,000 variable genes. An approximate 
principal component analysis was applied to the cells to generate 200 principal components 
(PCs). Using a combination of the Jackstraw function in Seurat and observing the “elbow” of the 
standard deviations of PCs, we chose the top 70 PCs for subsequent clustering and 
visualization. For 2D visualization, we used a Uniform Manifold Approximation and Projection 
(UMAP) dimensionality reduction technique (https://github.com/lmcinnes/umap) with “min_dist” 
set to 0.3 and “n_neighbors” set to 50. To identify clusters of transcriptionally-similar cells, we 
employed unsupervised clustering as described above using the FindClusters tool within the 
Seurat R package with default parameters and k.param set to 10. Resolution was chosen based 
on maximization of the average silhouette width across all cells. Clusters were merged if a cell 
type expressed fewer than 25 significantly upregulated genes by differential expression test 
(FindAllMarkers implemented in Seurat, setting “test.use” to “bimod”, Bonferroni-adjusted p-
value cutoff < 0.001). Differential expression tests between cells from saline-treated or IFNa 
treated mice were assessed using the FindMarkers function with “test.use” set to “bimod. This 
dataset can be visualized and downloaded here:  
https://singlecell.broadinstitute.org/single_cell/study/SCP832?scpbr=the-alexandria-
project#study-summary.  
 
Lung from MHV68 Infected and IFNγR KO Mice 
Libraries corresponding to 14 mice were aligned to a custom reference genome encompassing 
both murine (mm10) and herpes virus genes: 84 known genes from the murine herpesvirus 68 
were retrieved from NCBI (NCBI:txid33708) and added to the mm10 mouse genome. Reads 
were aligned to the custom joint genome and processed according to the Drop-Seq 
Computational Protocol v2.0 (https://github.com/broadinstitute/Drop-seq). Barcodes with < 200 
unique genes, > 20,000 UMI counts, and >30% of transcript counts derived from 
mitochondrially-encoded genes were discarded. Data analysis was performed using the Scanpy 
Package following the common procedure, the expression matrices were normalized using 
scran’s size factor based approach and log transformed via scanpy’s pp.log1p() function (Lun et 
al., 2016; Wolf et al., 2018). SoupX was utilized to reduce ambient RNA bias, using default 
parameters with pCut set to 0.3, and was applied to each sample before merging the count 
matrices (Young and Behjati, 2020). UMI per cell and cell cycle were regressed out. Highly 
variable genes were selected by running pp.highly_variable_genes() for each sample 
separately, returning the top 4,000 variable genes per sample, and genes identified in variable 
in >5 samples were retained, yielding 14,305 genes. Next, only Epcam+ cells were considered, 
principal components (PCs) were calculated using only the selected variable genes, and 6 PCs 
were used to perform unsupervised Louvain clustering. Type I Pneumocytes were excluded 
from this analysis based on uniformly negative expression of Ace2, resulting in a final dataset 
subset of 5,558 cells. Cells were identified as infected if at least one viral read was detected. 
 
Nasal Washes during Influenza Infection 
Sample processing, sequencing, and analysis was performed as in (Cao et al., 2020). Reads 
were aligned to the GRCh37 reference genome combined with influenza genomes. Mapped 
reads from each sample were then corrected for Drop-seq barcode synthesis error using the 
Drop-seq core computational tools developed by the McCarroll Lab (Macosko et al., 2015). 
Genes were quantified using End Sequence Analysis Toolkit (ESAT, github/garber-lab/ESAT) 
with parameters -wlen 100 -wOlap 50 -wExt 0 -scPrep (Derr et al., 2016). Finally, UMIs that 
likely result from sequencing errors were corrected by merging any UMIs that were observed 
only once and have 1 hamming distance from a UMI detected by two or more aligned reads. 
Only cell barcodes with more than 1,000 UMIs were analyzed. Cell barcodes with mostly 
erythrocyte genes (HBA, HBB) were removed. From here on, the remaining cell barcodes in the 
 
matrix would be referred to as cells. The final gene by cell matrix was normalized using the 
scran package v3.10 (Lun et al., 2016). The normalized matrix was used for dimensionality 
reduction by first selecting variable genes that had a high coefficient of variance (CV) and were 
expressed (>=1 UMI) by more than three cells. Influenza viral genes, interferon stimulated 
genes, and cell cycle related genes were removed from the variable gene list in order to 
minimize the impact of viral responses and mitosis on clustering and cell type identification. This 
resulted in the selection of 2484 variable genes. t-distributed stochastic neighbor embedding 
(tSNE) was applied to the first ten principal components (PCs), which explained 95% of the total 
data variance. Density clustering (Rodriguez and Laio, 2014) was performed on the resulting 
tSNE coordinates and identified four major clusters: epithelial cells, neutrophils, macrophages 
and leukocytes. The epithelial cell cluster and the leukocyte cluster were then re-clustered 
independently, as described above, to identify populations within each metacluster. Specifically, 
the epithelial cell cluster was re-embedded using 2629 variable genes selected by the same 
criteria mentioned in the previous section and 13 PCs that explained 95% of the variance. 
Density clustering over the epithelial cell subset revealed ten clusters. Differential gene 
expression analysis using edgeR (Robinson et al., 2010) was performed to identify marker 
genes for each cluster. Influenza-infected and bystander cells were identified after correcting for 
sample-specific distribution of ambient influenza mRNA contamination and predicted cells most 
likely to be infected identified using a hurdle zero inflated negative binomial (ZINB) model and a 
support vector machine (SVM) classifier. 
 
Power Calculations for Detection of Rare Transcripts  
We conducted the following statistical analysis to estimate the effects of various factors on our 
ability to make confident claims regarding the presence/absence of transcripts of interest (e.g., 
ACE2), both within individual cells and clusters (Figure S6). Specifically, we investigated the 
roles of capture/reverse transcription efficiency, ACE2 expression level, sequencing depth, and 
cell numbers. Taken together, the results of this power analysis are in agreement with other 
efforts to model biological and technical sources of zero-inflation within scRNA-seq data (e.g. 
https://satijalab.org/howmanycells and (Kharchenko et al., 2014; Svensson, 2020). 
 
We began by quantifying how likely we are to capture and transcribe at least one ACE2 mRNA 
molecule, as a function of the number ACE2 mRNA molecules per cell and a protocol’s 
efficiency (Figure S6A). Drop-Seq has a capture/transcription efficiency of ~10% (as estimated 
using ERCC spike ins; see (Macosko et al., 2015), and the experimental platforms used in this 
study are either equivalent (e.g., Seq-Well v1, (Gierahn et al., 2017) or superior (e.g., 10-fold 
better unique molecule detection, 5-fold better gene detection using Seq-Well S^3;(Hughes et 
al., 2019)). Most relevant to this context, inferior turbinate scrapings were processed using both 
Seq-Well v1 and Seq-Well S^3 (Figure S3B). Importantly, Seq-Well S^3 provided > two-fold 
increase in the detection frequency of rare ACE2 transcripts (i.e., ACE2+: 4.7% for v1 vs. 9.8% 
for S^3), making it reasonable to expect that such improvements in single-cell experimental 
technologies have yielded corresponding improvements in capture and transcription efficiency. 
Based on Drop-Seq’s 10% efficiency, even if ACE2 is expressed at the low level of 5 mRNA 
molecules per cell (a reasonable order-of-magnitude estimate, given that non-human primate 
ileum cells had a maximum of 10 ACE2 unique molecules per cell observed via sequencing and 
an average of 1.93 molecules per cell in expressing cells, see Figure 3B,C), our experimental 
platforms have a minimum likelihood of 41% to capture and reverse transcribe at least one 
ACE2 mRNA molecule in any given individual cell. This likelihood rapidly increases if we 
estimate higher efficiencies for improved scRNA-seq technologies (e.g., 67% likelihood within 
any individual cell at 20% capture/transcription efficiency, 76% likelihood at 25% efficiency, 
Figure S6A). Thus, while transcript drop-out may reduce the fraction of positive cells, with the 
 
capture and transcription efficiencies of improved single-cell technologies, the impact is likely to 
be minor (reads are likely underestimated by up to a factor of ~2.5x), given a sufficient depth of 
sequencing (see below). We note that this impacts both clusters deemed to contain and not 
contain ACE2+ cells, and suggests our percentages are likely lower bounds for true expression 
(within a factor of ~2.5x).  
 
Next, we examined the probability of sequencing an ACE2 transcript as a function of read depth 
and ACE2’s fractional abundance in each single cell within our sequencing libraries. First, 
across two different tissues (non-human primate ileum and lung, representing a high expresser 
of ACE2 and low expresser, respectively), we calculated the proportion of unique ACE2 
molecules in our ACE2+ cells (defined as any cell with at least 1 UMI aligning to ACE2) as a 
fraction of total reads within individual cells to provide an order-of-magnitude estimate for 
average ACE2 abundance in our single-cell sequencing libraries (i.e., the probability that a read 
within a cell corresponds to a unique molecule of ACE2, Figure S6B). We highlight that by 
calculating probabilities based on ACE2 unique molecules divided by an individual cell’s total 
reads, we are providing a conservative estimate for the probability of observing ACE2 as a 
function of sequencing depth (e.g., as compared to basing these probabilities on ACE2 non-
UMI-collapsed reads divided by total reads). Next, we obtained information on the number of 
reads in these cell populations to provide estimates of average sequencing depths (Figure 
S6C). Using the mean fractional abundances of ACE2 from each tissue (Figure S6B) and the 
mean read depths for all genes (Figure S6C), we calculated the probability of detecting at least 
1 ACE2 molecule (i.e., P(detecting >0 ACE2 molecules) = 1 - (1 - ACE2 fractional 
abundance)Read depth). This results in a 93.7% probability in ileum-derived cell libraries that 
contain ACE2, and a 76.0% probability for lung-derived cell libraries, indicating that our 
sequencing depths are sufficient to detect ACE2+ cells (Figure S6D).  
 
To further evaluate whether our ability to detect ACE2+ cells was an artifact of sequencing 
depth, we compared the number of ACE2+ cells in a cluster to the mean number of reads 
across all cells in that same cluster (Figure S6E). We did not observe any significant 
correlation: the ileum cell cluster with the highest number of ACE2+ cells had the lowest 
sequencing depth of all ileum clusters, and the lung cell cluster with the highest number of 
ACE2+ cells was approximately average in its read depth (on a log-log scale, Pearson’s r = -
0.31, non-significant). Further, when comparing ACE2+ cells to ACE2- cells within a given 
tissue, we did not observe a positive correlation between read depth and ACE2 status (i.e., 
mean +/- standard error of the mean, SEM, reads among all lung cells = 28,512 +/- 344; mean 
+/- SEM reads among ACE2+ lung cells = 28,553 +/- 2,988; mean +/- SEM reads among all 
ileum cells = 14,864 +/- 288; mean +/- SEM reads among ACE2+ ileum cells = 10,591 +/- 441, 
full statistics on cell depth among ACE2+ cells compared to ACE2- cells of the same cell type 
can be found in Table S9). Thus, we can be confident that the observed differences in ACE2+ 
proportions across clusters are not driven by differences in sequencing depth.  
 
Finally, we investigated how observed differences in ACE2+ proportions across clusters might 
be affected by cell sampling. Using the proportion of ACE2+ cells in a “typical” cluster annotated 
as being ACE2 positive (i.e., 6.8% in non-human primate type II pneumocytes, Figure 1), we 
calculated the cluster sizes needed to be confident that the probability of observing zero to a 
few positive cells is unlikely to have arisen by random chance (probabilities calculated under a 
negative binomial distribution with parameter P = 0.068, Figure S6E). We found that as cluster 
sizes approach and exceed 100 cells, the probability of observing zero to a few positive cells 
rapidly approaches zero, if we assume 6.8% of cells are positive. Further, to examine our 
confidence in estimating an approximate upper bound (ignoring the impact of protocol 
inefficiencies discussed above) for the fraction of cells positive in a cluster as a function of the 
 
number of cells in that cluster, we also calculated the probability of observing zero (and its 
complement, probability of observing at least 1) ACE2+ cells as a function of cluster size across 
true positive proportions ranging from 0.1% to 10% (probabilities calculated under a negative 
binomial distribution with parameter P = 0.001 to 0.1, representing hypothetical proportions of 
ACE2+ cells Figure S6F). Given our typical cluster sizes (on the order of hundreds of cells, 
exact values provided in Table S9), we find that for us to observe 0 ACE2+ cells in a cluster due 
to sampling artifacts, the fraction of true positives must be ~1% or less. Thus, these 
complementary approaches demonstrate that our observed variations in ACE2+ cell proportions 
across clusters likely reflect underlying biological differences, rather than random chance.  
 
Statistical Testing 
Parameters such as sample size, number of replicates, number of independent experiments, 
measures of center, dispersion, and precision (mean +/- SEM) and statistical significances are 
reported in Figures and Figure Legends. A p-value less than 0.05 was considered significant. 
Where appropriate, a Bonferroni correction was used to account for multiple tests, alternative 
correction methods are noted in the figure legends or Methods. All statistical tests 
corresponding to differential gene expression are described above and completed using R 
language for Statistical Computing. 
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Highlights: 
•  Meta-analysis of human, primate & mouse scRNA-seq for putative SARS-CoV-2 targets 
•  Type II pneumocytes, nasal secretory cells & absorptive enterocytes are ACE2+TMPRSS2+ 
•  Interferon & influenza increase ACE2 in human nasal epithelia and lung tissue 
•  Mouse Ace2 is not upregulated by interferon, raising implications for disease models 
 
 
eTOC Blurb: 
Analysis of single-cell RNA-seq datasets from human, non-human primate, and mouse barrier tissues 
identifies putative cellular targets of SARS-CoV-2 based on ACE2 and TMPRSS2 expression. ACE2 
represents a previously-unappreciated interferon stimulated gene in human, but not mouse, epithelial 
tissues, identifying anti-viral induction of a host tissue-protective mechanism, but also a potential means 
for viral exploitation of the host response. 
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